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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available),
plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise
Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time
record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full. Ligand-gated ion channels are one of the eight
major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic
receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16
and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology
(NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
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Overview: Ligand-gated ion channels (LGICs) are integral mem-
brane proteins that contain a pore which allows the regulated ﬂow
of selected ions across the plasma membrane. Ion ﬂux is pas-
sive and driven by the electrochemical gradient for the perme-
ant ions. These channels are open, or gated, by the binding of a
neurotransmitter to an orthosteric site(s) that triggers a conforma-
tional change that results in the conducting state. Modulation of
gating can occur by the binding of endogenous, or exogenous,
modulators to allosteric sites. LGICs mediate fast synaptic trans-
mission, on a millisecond time scale, in the nervous system and at
the somatic neuromuscular junction. Such transmission involves
the release of a neurotransmitter from a pre-synaptic neurone and
the subsequent activation of post-synaptically located receptors
that mediate a rapid, phasic, electrical signal (the excitatory, or
inhibitory, post-synaptic potential). However, in addition to their
traditional role in phasic neurotransmission, it is now established
that some LGICs mediate a tonic form of neuronal regulation that
results from the activation of extra-synaptic receptors by ambient
levels of neurotransmitter. The expression of some LGICs by non-
excitable cells is suggestive of additional functions.
By convention, the LGICs comprise the excitatory, cation-
selective, nicotinic acetylcholine [54, 257], 5-HT3 [21, 386],
ionotropic glutamate [231, 365] and P2X receptors [174, 349] and
the inhibitory, anion-selective, GABAA [27, 287] and glycine re-
ceptors [233, 399]. The nicotinic acetylcholine, 5-HT3, GABAA
and glycine receptors (and an additional zinc-activated channel)
are pentameric structures and are frequently referred to as the Cys-
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loop receptors due to the presence of a deﬁning loop of residues
formed by a disulphide bond in the extracellular domain of their
constituent subunits [259, 353]. However, the prokaryotic ances-
tors of these receptors contain no such loop and the term pen-
tameric ligand-gated ion channel (pLGIC) is gaining acceptance in
the literature [145]. The ionotropic glutamate and P2X receptors
are tetrameric and trimeric structures, respectively. Multiple genes
encode the subunits of LGICs and the majority of these receptors
are heteromultimers. Such combinational diversity results, within
each class of LGIC, in a wide range of receptors with differing phar-
macological and biophysical properties and varying patterns of ex-
pression within the nervous system and other tissues. The LGICs
thus present attractive targets for new therapeutic agents with im-
proved discrimination between receptor isoforms and a reduced
propensity for off-target effects. The development of novel, faster
screening techniques for compounds acting on LGICs [100] will
greatly aid in the development of such agents.
Family structure
S131 5-HT3 receptors
S133 Acid-sensing (proton-gated) ion channels (ASICs)
S135 Epithelial sodium channels (ENaC)
S137 GABAA receptors
S142 Glycine receptors
S144 Ionotropic glutamate receptors
S149 IP3 receptor
S150 Nicotinic acetylcholine receptors
S154 P2X receptors
S156 ZAC
5-HT3 receptors
Ligand-gated ion channels → 5-HT3 receptors
Overview: The 5-HT3 receptor (nomenclature as agreed by
the NC-IUPHAR Subcommittee on 5-Hydroxytryptamine
(serotonin) receptors [157]) is a ligand-gated ion channel of
the Cys-loop family that includes the zinc-activated channels,
nicotinic acetylcholine, GABAA and strychnine-sensitive glycine
receptors. The receptor exists as a pentamer of 4TM subunits that
form an intrinsic cation selective channel [21]. Five human 5-
HT3 receptor subunits have been cloned and homo-oligomeric as-
semblies of 5-HT3A and hetero-oligomeric assemblies of 5-HT3A
and 5-HT3B subunits have been characterised in detail. The 5-
HT3C (HTR3C, Q8WXA8), 5-HT3D (HTR3D, Q70Z44) and 5-HT3E
(HTR3E, A5X5Y0) subunits [189, 277], like the 5-HT3B subunit,
do not form functional homomers, but are reported to assemble
with the 5-HT3A subunit to inﬂuence its functional expression
rather than pharmacological proﬁle [148, 279, 379]. 5-HT3A, -C,
-D, and -E subunits also interact with the chaperone RIC-3 which
predominantly enhances the surface expression of homomeric 5-
HT3A receptor [379]. The co-expression of 5-HT3A and 5-HT3C-E
subunits has been demonstrated in human colon [186]. A recom-
binant hetero-oligomeric 5-HT3AB receptor has been reported to
contain two copies of the 5-HT3A subunit and three copies of the
5-HT3B subunit in the order B-B-A-B-A [25], but this is inconsistent
with recent reports which show at least one A-A interface [225,
357]. The 5-HT3B subunit imparts distinctive biophysical prop-
erties upon hetero-oligomeric 5-HT3AB versus homo-oligomeric
5-HT3A recombinant receptors [77, 98, 135, 176, 194, 301, 344],
inﬂuences the potency of channel blockers, but generally has only
a modest effect upon the apparent afﬁnity of agonists, or the afﬁn-
ity of antagonists ([41], but see [76, 81, 98]) which may be ex-
plained by the orthosteric binding site residing at an interface
formed between 5-HT3A subunits [225, 357]. However, 5-HT3A
and 5-HT3AB receptors differ in their allosteric regulation by some
general anaesthetic agents, small alcohols and indoles [158, 317,
341]. The potential diversity of 5-HT3 receptors is increased by
alternative splicing of the genes HTR3A and E [44, 151, 276, 278,
279]. In addition, the use of tissue-speciﬁc promoters driving ex-
pression fromdifferent transcriptional start sites has been reported
for the HTR3A, HTR3B, HTR3D and HTR3E genes, which could re-
sult in 5-HT3 subunits harbouring different N-termini [176, 276,
366]. To date, inclusion of the 5-HT3A subunit appears imperative
for 5-HT3 receptor function.
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Nomenclature 5-HT3AB 5-HT3A
Subunits 5-HT3A, 5-HT3B 5-HT3A
Selective agonists – meta-chlorphenylbiguanide [26, 77, 214, 262, 263], 2-methyl-5-HT [26, 77, 214,
262], SR57227A [102] – Rat, 1-phenylbiguanide [26]
Antagonists – vortioxetine (pKi 8.4) [18], metoclopramide (pKi 6–6.4) [41, 152]
Selective antagonists – palonosetron (pKi 10.5) [269], alosetron (pKi 9.5) [146], (S)-zacopride (pKi 9) [41],
granisetron (pKi ∼8.6–8.8) [152, 262], tropisetron (pKi 8.5–8.8) [214, 262],
ondansetron (pKi ∼7.8–8.3) [41, 152, 262]
Channel blockers picrotoxinin (pIC50 4.2) [352], bilobalide (pIC50 2.5) [352], ginkgolide B (pIC50 2.4)
[352]
picrotoxinin (pIC50 5) [351], TMB-8 (pIC50 4.9) [348], diltiazem (pIC50 4.7) [351],
bilobalide (pIC50 3.3) [351], ginkgolide B (pIC50 3.1) [351]
Labelled ligands – [3H]ramosetron (Antagonist) (pKd 9.8) [262], [
3H]GR65630 (Antagonist) (pKd
8.6–9.3) [146, 214], [3H]granisetron (Antagonist) (pKd 8.9) [41, 152],
[3H](S)-zacopride (Antagonist) (pKd 8.7) [293], [
3H]LY278584 (Antagonist) (pKd 8.5)
[1]
Functional Characteristics γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly rectifying current [+ 5-HT3B,
rectiﬁcation reduced]; nH 2-3 [+ 5-HT3B 1-2]; relative permeability to divalent cations
reduced by co-expression of the 5-HT3B subunit
γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly rectifying current [+ 5-HT3B,
rectiﬁcation reduced]; nH 2-3 [+ 5-HT3B 1-2]; relative permeability to divalent cations
reduced by co-expression of the 5-HT3B subunit
Subunits
Nomenclature 5-HT3A 5-HT3B 5-HT3C 5-HT3D 5-HT3E
HGNC, UniProt HTR3A, P46098 HTR3B, O95264 HTR3C, Q8WXA8 HTR3D, Q70Z44 HTR3E, A5X5Y0
Functional Characteristics γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly
rectifying current [+ 5-HT3B, rectiﬁcation reduced];
nH 2-3 [+ 5-HT3B 1-2]; relative permeability to
divalent cations reduced by co-expression of the
5-HT3B subunit
γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly
rectifying current [+ 5-HT3B, rectiﬁcation reduced];
nH 2-3 [+ 5-HT3B 1-2]; relative permeability to
divalent cations reduced by co-expression of the
5-HT3B subunit
– – –
Comments: Quantitative data in the table refer to homo-
oligomeric assemblies of the human 5-HT3A subunit, or the re-
ceptor native to human tissues. Signiﬁcant changes introduced
by co-expression of the 5-HT3B subunit are indicated in parenthe-
sis. Although not a selective antagonist, methadone displays mul-
timodal and subunit-dependent antagonism of 5-HT3 receptors
[81]. Similarly, TMB-8, diltiazem, picrotoxin, bilobalide and
ginkgolide B are not selective for 5-HT3 receptors (e.g.[352]). The
anti-malarial drugsmeﬂoquine and quinine exert amodestlymore
potent block of 5-HT3A versus 5-HT3AB receptor-mediated re-
sponses [354]. Known better as a partial agonist of nicotinic acetyl-
choline α4β2 receptors, varenicline is also an agonist of the 5-
HT3A receptor [231]. Human [26, 262], rat [164], mouse [243],
guinea-pig [214] ferret [264] and canine [178] orthologues of the 5-
HT3A receptor subunit have been cloned that exhibit intraspecies
variations in receptor pharmacology. Notably, most ligands dis-
play signiﬁcantly reduced afﬁnities at the guinea-pig 5-HT3 recep-
tor in comparison with other species. In addition to the agents
listed in the table, native and recombinant 5-HT3 receptors are
subject to allosteric modulation by extracellular divalent cations,
alcohols, several general anaesthetics and 5-hydroxy- and halide-
substituted indoles (see reviews [294, 355, 356, 380]).
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Further reading on 5-HT3 receptors
Andrews, PL et al. (2014) Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol 722:
108-21 [PMID:24157981]
Fakhfouri, G et al. (2015) From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic
Opportunities for 5-HT3 Receptor Antagonists. Mol Neurobiol 52: 1670-1679 [PMID:25377794]
Gupta, D et al. (2016) 5HT3 receptors: Target for new antidepressant drugs. Neurosci Biobehav Rev
64: 311-25 [PMID:26976353]
Hoyer, D et al. (1994) International Union of Pharmacology classiﬁcation of receptors for 5-
hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203
Lochner, M et al. (2015) A review of ﬂuorescent ligands for studying 5-HT3 receptors. Neurophar-
macology 98: 31-40 [PMID:25892507]
Rojas, C et al. (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in preven-
tion of emesis. Eur J Pharmacol 722: 26-37 [PMID:24184669]
Acid-sensing (proton-gated) ion channels (ASICs)
Ligand-gated ion channels → Acid-sensing (proton-gated) ion channels (ASICs)
Overview: Acid-sensing ion channels (ASICs,nomenclature as
agreed by NC-IUPHAR [193]) are members of a Na+ channel
superfamily that includes the epithelial Na+ channel (ENaC), the
FMRF-amide activated channel (FaNaC) of invertebrates, the de-
generins (DEG) of Caenorhabitis elegans, channels in Drosophila
melanogaster and ’orphan’ channels that include BLINaC [325]
and INaC [323] that have also been named BASICs, for bile acid-
activated ion channels [383]. ASIC subunits contain two TM do-
mains and assemble as homo- or hetero-trimers [17, 125, 175]
to form proton-gated, voltage-insensitive, Na+ permeable, chan-
nels (reviewed in [131, 382]). Splice variants of ASIC1 [provision-
ally termed ASIC1a (ASIC, ASICα, BNaC2α) [376], ASIC1b (ASICβ,
BNaC2β) [61] and ASIC1b2 (ASICβ2) [367]; note that ASIC1a is
also permeable to Ca2+] and ASIC2 [provisionally termed ASIC2a
(MDEG1, BNaC1α, BNC1α) [121, 308, 377] and ASIC2b (MDEG2,
BNaC1β) [223]] have been cloned. Unlike ASIC2a (listed in table),
heterologous expression of ASIC2b alone does not support H+-
gated currents. A third member, ASIC3 (DRASIC, TNaC1) [375],
has been identiﬁed. A fourth mammalian member of the family
(ASIC4/SPASIC) does not support a proton-gated channel in het-
erologous expression systems and is reported to downregulate the
expression of ASIC1a and ASIC3 [1, 92, 130, 222]. ASIC chan-
nels are primarily expressed in central and peripheral neurons in-
cluding nociceptors where they participate in neuronal sensitivity
to acidosis. They have also been detected in taste receptor cells
(ASIC1-3), photoreceptors and retinal cells (ASIC1-3), cochlear
hair cells (ASIC1b), testis (hASIC3), pituitary gland (ASIC4), lung
epithelial cells (ASIC1a and -3), urothelial cells, adipose cells
(ASIC3), vascular smooth muscle cells (ASIC1-3), immune cells
(ASIC1,-3 and -4) and bone (ASIC1-3). A neurotransmitter-like
function of protons has been suggested, involving postsynapti-
cally located ASICs of the CNS in functions such as learning and
fear perception [97, 207, 408], responses to focal ischemia [390]
and autoimmune inﬂammation [115], as well as seizures [408] and
pain [37, 84, 85, 89]. Heterologously expressed heteromultimers
form ion channels with differences in kinetics, ion selectivity, pH-
sensitivity and sensitivity to blockers that resemble some of the
native proton activated currents recorded from neurones [15, 24,
107, 223].
Nomenclature ASIC1 ASIC2
HGNC, UniProt ASIC1, P78348 ASIC2, Q16515
Endogenous activators Extracellular H+ (ASIC1a) (pEC50 ∼6.2–6.8), Extracellular H+ (ASIC1b) (pEC50 ∼5.1–6.2) Extracellular H+ (pEC50 ∼4.1–5)
Channel blockers psalmotoxin 1 (ASIC1a) (pIC50 9), Zn2+ (ASIC1a) (pIC50 ∼8.2), Pb2+ (ASIC1b) (pIC50 ∼5.8),
A-317567 (ASIC1a) (pIC50 ∼5.7) [99] – Rat, Pb2+ (ASIC1a) (pIC50 ∼5.4), amiloride (ASIC1a) (pIC50
5), benzamil (ASIC1a) (pIC50 5), ethylisopropylamiloride (ASIC1a) (pIC50 5), nafamostat (ASIC1a)
(pIC50 ∼4.9), amiloride (ASIC1b) (pIC50 4.6–4.7), ﬂurbiprofen (ASIC1a) (pIC50 3.5) [372] – Rat,
ibuprofen (ASIC1a) (pIC50 ∼3.5), Ni2+ (ASIC1a) (pIC50 ∼3.2)
amiloride (pIC50 4.6), A-317567 (pIC50 ∼4.5), nafamostat (pIC50 ∼4.2),
Cd2+ (pIC50 ∼3)
Labelled ligands [125I]psalmotoxin 1 (ASIC1a) (pKd 9.7) –
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(continued)
Nomenclature ASIC1 ASIC2
Functional Characteristics ASIC1a: γ ˜14pS
PNa/PK = 5-13, PNa/PCa =2.5
rapid activation rate (5.8-13.7 ms), rapid inactivation rate (1.2-4 s) @ pH 6.0, slow recovery
(5.3-13s) @ pH 7.4
ASIC1b: γ ˜19 pS
PNa/PK =14.0, PNa  PCa
rapid activation rate (9.9 ms), rapid inactivation rate (0.9-1.7 s) @ pH 6.0, slow recovery (4.4-7.7 s)
@ pH 7.4
γ ˜10.4-13.4 pS
PNa/PK =10, PNa/PCa = 20
rapid activation rate, moderate inactivation rate (3.3-5.5 s) @ pH 5
Comments ASIC1a and ASIC1b are also blocked by diarylamidines (IC50 ˜3 μM for ASIC1a) ASIC2 is also blocked by diarylamidines
Nomenclature ASIC3
HGNC, UniProt ASIC3, Q9UHC3
Endogenous activators Extracellular H+ (transient component) (pEC50 ∼6.2–6.7), Extracellular H+ (sustained component) (pEC50 ∼3.5–4.3)
Activators GMQ (largly non-desensitizing; at pH 7.4) (pEC50 ∼3), arcaine (at pH 7.4) (pEC50 ∼2.9), agmatine (at pH 7.4) (pEC50 ∼2)
Channel blockers APETx2 (transient component only) (pIC50 7.2), nafamostat (transient component) (pIC50 ∼5.6), A-317567 (pIC50 ∼5), amiloride (transient component only - sustained
component enhanced by 200μM amiloride at pH 4) (pIC50 4.2–4.8), Gd3+ (pIC50 4.4), Zn2+ (pIC50 4.2), aspirin (sustained component) (pIC50 4) [372], diclofenac (sustained
component) (pIC50 4), salicylic acid (sustained component) (pIC50 3.6)
Functional Characteristics γ ˜13-15 pS;
biphasic response consisting of rapidly inactivating transient and sustained components;
very rapid activation (<5 ms) and inactivation (0.4 s);
fast recovery (0.4-0.6 s) @ pH 7.4, transient component partially inactivated at pH 7.2
Comments ASIC3 is also blocked by diarylamidines
Comments: psalmotoxin 1 (PcTx1) inhibits ASIC1a by increas-
ing the afﬁnity to H+ and promoting channel desensitization [64,
107]. PcTx1 has little effect on ASIC2a, ASIC3 or ASIC1a ex-
pressed as a heteromultimer with either ASIC2a, or ASIC3 but
does inhibit ASIC1a expressed as a heteromultimer with ASIC2b
[330]. ASIC1-containing homo- and heteromers are inhibited
by Mambalgins, toxins contained in the black mamba venom,
which induce in ASIC1a an acidic shift of the pH dependence of
activation [89]. APETx2 most potently blocks homomeric
ASIC3 channels, but also ASIC2b+ASIC3, ASIC1b+ASIC3, and
ASIC1a+ASIC3 heteromeric channels with IC50 values of 117 nM,
900 nM and 2 μM, respectively. APETx2 has no effect on ASIC1a,
ASIC1b, ASIC2a, or ASIC2a+ASIC3 [88, 90]. APETx2 inhibits
however also voltage-gated Na+ channels [34, 297]. IC50 val-
ues for A-317567 are inferred from blockade of ASIC channels
native to dorsal root ganglion neurones [99]. The pEC50 val-
ues for proton activation of ASIC channels are inﬂuenced by nu-
merous factors including extracellular di- and poly-valent ions,
Zn2+, protein kinase C and serine proteases (reviewed in [193,
382]). Rapid acidiﬁcation is required for activation of ASIC1 and
ASIC3 due to fast inactivation/desensitization. pEC50 values for
H+-activation of either transient, or sustained, currents mediated
by ASIC3 vary in the literature and may reﬂect species and/or
methodological differences [16, 79, 375]. The transient ASIC cur-
rent component is Na+-selective (PNa/PK of about 10) [375, 392]
whereas the sustained current component that is observed with
ASIC3 and some ASIC heteromers is non-selective between Na+
and K+ [79]. The reducing agents dithiothreitol (DTT) and glu-
tathione (GSH) increase ASIC1a currents expressed in CHO cells
and ASIC-like currents in sensory ganglia and central neurons
[8, 68] whereas oxidation, through the formation of intersub-
unit disulphide bonds, reduces currentsmediated by ASIC1a [405].
ASIC1a is also irreversibly modulated by extracellular serine pro-
teases, such as trypsin, through proteolytic cleavage [373]. Non-
steroidal anti-inﬂammatory drugs (NSAIDs) are direct inhibitors
of ASIC currents (reviewed in [22]). Extracellular Zn2+ potentiates
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proton activation of homomeric and heteromeric channels incor-
porating ASIC2a, but not homomeric ASIC1a or ASIC3 channels
[23]. However, removal of contaminating Zn2+ by chelation re-
veals a high afﬁnity block of homomeric ASIC1a and heteromeric
ASIC1a+ASIC2 channels by Zn2+ indicating complex biphasic ac-
tions of the divalent [69]. Nitric oxide potentiates submaximal
currents activated by H+ mediated by ASIC1a, ASIC1b, ASIC2a
and ASIC3 [47]. Ammonium ions activate ASIC channels (most
likely ASIC1a) in midbrain dopaminergic neurones: that may
be relevant to neuronal disorders associated with hyperammone-
mia [302]. The positive modulation of homomeric, heteromeric
and native ASIC channels by the peptide FMRFamide and re-
lated substances, such as neuropeptides FF and SF, is reviewed
in detail in [369]. Inﬂammatory conditions and particular pro-
inﬂammatory mediators such as arachidonic acid induce overex-
pression of ASIC-encoding genes and enhance ASIC currents [85,
241, 337]. The sustained current component mediated by ASIC3
is potentiated by hypertonic solutions in a manner that is syner-
gistic with the effect of arachidonic acid [85]. ASIC3 is partially
activated by the lipids lysophosphatidylcholine (LPC) and arachi-
donic acid [244]. Mit-Toxin, which is contained in the venom of
the Texas coral snake, activates several ASIC subtypes [37]. Selec-
tive activation of ASIC3 by GMQ at a site separate from the proton
binding site is potentiated by mild acidosis and reduced extracel-
lular Ca2+ [402].
Further reading on Acid-sensing (proton-gated) ion channels (ASICs)
Baron A et al. (2015) Pharmacology of acid-sensing ion channels - Physiological and therapeutical
perspectives. Neuropharmacology 94: 19-35 [PMID:25613302]
Boscardin E et al. (2016) The function and regulation of acid-sensing ion channels (ASICs) and
the epithelial Na(+) channel (ENaC): IUPHAR Review 19. Br J Pharmacol 173: 2671-701
[PMID:27278329]
Grunder S et al. (2015) Biophysical properties of acid-sensing ion channels (ASICs). Neuropharma-
cology 94: 9-18 [PMID:25585135]
Kellenberger S et al. (2015) International Union of Basic and Clinical Pharmacology. XCI. struc-
ture, function, and pharmacology of acid-sensing ion channels and the epithelial Na+ channel.
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Epithelial sodium channels (ENaC)
Ligand-gated ion channels → Epithelial sodium channels (ENaC)
Overview: The epithelial sodium channels (ENaC) mediate
sodium reabsorption in the aldosterone-sensitive distal part of the
nephron and the collecting duct of the kidney. ENaC is assem-
bled as a heterotrimer composed of three subunits α, β, and γ or
δ, β, and γ [137]. These subunits consitute a family within the
ENaC/Degenerin super-family [137]. Genes encoding ENaC sub-
units are found in all vertebrates with the exception of ray-ﬁnned
ﬁshes [137]. ENaC composed of α, β, and γ subunits is located
mostly in tight or high-resistance epithelial tissues such as the
airways, distal colon and exocrine glands [104]. ENaC activity
is tightly regulated in the kidney by aldosterone, angiotensin II
(AGT, P01019), vasopressin (AVP, P01185), insulin (INS, P01308)
and glucocorticoids; this ﬁne regulation of ENaC is essential to
maintain sodium balance between daily intake and urinary ex-
cretion of sodium, circulating volume and blood pressure. ENaC
expression is also vital for clearance of foetal lung ﬂuid, and
to maintain air-surface-liquid [160, 227]. Sodium reabsorption
is suppressed by the ‘potassium-sparing’ diuretics amiloride and
triamterene. ENaC is a heteromultimeric channel made of homol-
ogous α β and γ subunits. The primary structure of the α ENaC
subunit was identiﬁed by expression cloning [48, 137]; β and γ
ENaC subunits were identiﬁed by functional complementation of
the α subunit [49, 137]. Each ENaC subunit contains 2 TM α he-
lices connected by a large extracellular loop and short cytoplasmic
amino- and carboxy-termini. The stoichiometry of the epithelial
sodium channel in the kidney and related epithelia is, by homol-
ogy with the structurally related channel ASIC1a, thought to be a
heterotrimer of 1α:1β:1γ subunits [125].
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Nomenclature ENaCαβγ
Subunits ENaC β, ENaC α, ENaC γ
Activators S3969 (pEC50 5.9) [229]
Channel blockers P552-02 (pIC50 8.1), benzamil (pIC50 ∼8), amiloride (pIC50 6.7–7), triamterene (pIC50 ∼5.3) [49, 192]
Functional Characteristics γ ≈ 4-5 pS, PNa/PK > 20; tonically open at rest; expression and ion ﬂux regulated by circulating aldosterone-mediated changes in gene transcription. The action of aldosterone,
which occurs in ‘early’ (1.5–3 h) and ‘late’ (6-24 hr) phases is competitively antagonised by spironolactone, its active metabolites and eplerenone. Glucocorticoids are important
functional regulators in lung/airways and this control is potentiated by thyroid hormone; but the mechanism underlying such potentiation is unclear [19, 311, 322]. The density of
channels in the apical membrane, and hence GNa, can be controlledvia both serum and glucocorticoid-regulated kinases (SGK1, 2 and 3) [80, 114] and via cAMP/PKA [267]; and
these protein kinases appear to act by inactivating Nedd-4/2, a ubiquitin ligase that normally targets the ENaC channel complex for internalization and degradation [35, 80]. ENaC
is constitutively activated by soluble and membrane-bound serine proteases, such as furin, prostasin (CAP1), plasmin and elastase [202, 203, 305, 313, 314]. The activation of
ENaC by proteases is blocked by a protein, SPLUNC1, secreted by the airways and which binds speciﬁcally to ENaC to prevent its cleavage [120]. Pharmacological inhibitors of
proteases (e.g. camostat acting upon prostasin) reduce the activity of ENaC [237]. Phosphatidylinositides such as PtIns(4,5)P2 and PtIns(3,4,5)P3) stabilise channel gating probably
by binding to the β and γ ENaC subunits, respectively [235, 307], whilst C terminal phosphorylation of β and γ-ENaC by ERK1/2 has been reported to inhibit the withdrawal of the
channel complex from the apical membrane [393]. This effect may contribute to the cAMP-mediated increase in sodium conductance.
Subunits
Nomenclature ENaC α ENaC β ENaC δ ENaC γ
HGNC, UniProt SCNN1A, P37088 SCNN1B, P51168 SCNN1D, P51172 SCNN1G, P51170
Comments: Data in the table refer to the αβγ heteromer. There
are several human diseases resulting frommutations in ENaC sub-
units [137]. Liddle’s syndrome (including features of salt-sensitive
hypertension and hypokalemia), is associated with gain of func-
tion mutations in the β and γ subunits leading to defective ENaC
ubiquitylation and increased stability of active ENaC at the cell
surface [137, 314, 324, 343]. Enzymes that deubiquitylate ENaC
increase its function in vivo. Pseudohypoaldosteronism type 1
(PHA-1) can occur through either mutations in the gene encoding
the mineralocorticoid receptor, or loss of function mutations in
genes encoding ENaC subunits [39, 137]. Regulation of ENaC by
phosphoinositides may underlie insulin ( INS, P01308)-evoked re-
nal Na+ retention that can complicate the clinical management of
type 2 diabetes using insulin-sensitizing thiazolidinedione drugs
[132].
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GABAA receptors
Ligand-gated ion channels → GABAA receptors
Overview: The GABAA receptor is a ligand-gated ion channel of
the Cys-loop family that includes the nicotinic acetylcholine, 5-
HT3 and strychnine-sensitive glycine receptors. GABAA receptor-
mediated inhibition within the CNS occurs by fast synaptic
transmission, sustained tonic inhibition and temporally interme-
diate events that have been termed ‘GABAA, slow’ [51]. GABAA re-
ceptors exist as pentamers of 4TM subunits that form an intrinsic
anion selective channel. Sequences of six α, three β, three γ, one
δ, three ρ, one , one π and one θ GABAA receptor subunits have
been reported in mammals [286, 287, 331, 333]. The π -subunit
is restricted to reproductive tissue. Alternatively spliced versions
of many subunits exist (e.g. α4- and α6- (both not functional)
α5-, β2-, β3- and γ2), along with RNA editing of the α3 subunit
[75]. The three ρ-subunits, (ρ1-3) function as either homo- or
hetero-oligomeric assemblies [60, 406]. Receptors formed from
ρ-subunits, because of their distinctive pharmacology that in-
cludes insensitivity to bicuculline, benzodiazepines and barbitu-
rates, have sometimes been termed GABAC receptors [406], but
they are classiﬁed as GABAA receptors by NC-IUPHAR on
the basis of structural and functional criteria [20, 286,
287].
Many GABAA receptor subtypes contain α-, β- and γ-subunits with
the likely stoichiometry 2α.2β.1γ [206, 287]. It is thought that
the majority of GABAA receptors harbour a single type of α- and
β -subunit variant. The α1β2γ2 hetero-oligomer constitutes the
largest population of GABAA receptors in the CNS, followed by
the α2β3γ2 and α3β3γ2 isoforms. Receptors that incorporate the
α4- α5-or α6-subunit, or the β1-, γ1-, γ3-, δ-, - and θ -subunits, are
less numerous, but they may nonetheless serve important func-
tions. For example, extrasynaptically located receptors that con-
tain α6- and δ-subunits in cerebellar granule cells, or an α4- and
δ-subunit in dentate gyrus granule cells and thalamic neurones,
mediate a tonic current that is important for neuronal excitabil-
ity in response to ambient concentrations of GABA [27, 109, 265,
327, 338]. GABA binding occurs at the β+/α- subunit interface
and the homologous γ+/α- subunits interface creates the benzodi-
azepine site. A second site for benzodiazepine binding has recently
been postulated to occur at the α+/β- interface ([310]; reviewed by
[332]). The particular α-and γ-subunit isoforms exhibit marked
effects on recognition and/or efﬁcacy at the benzodiazepine site.
Thus, receptors incorporating either α4- or α6-subunits are not
recognised by ‘classical’ benzodiazepines, such as ﬂunitrazepam
(but see [400]). The trafﬁcking, cell surface expression, internal-
isation and function of GABAA receptors and their subunits are
discussed in detail in several recent reviews [66, 166, 232, 371]
but one point worthy of note is that receptors incorporating the γ2
subunit (except when associated with α5) cluster at the postsynap-
tic membrane (but may distribute dynamically between synaptic
and extrasynaptic locations), whereas as those incorporating the
d subunit appear to be exclusively extrasynaptic.
NC-IUPHAR [20, 287] class the GABAA receptors according to
their subunit structure, pharmacology and receptor function. Cur-
rently, eleven native GABAA receptors are classed as conclusively
identiﬁed (i.e., α1β2γ2, α1βγ2, α3βγ2, α4βγ2, α4β2δ, α4β3δ, α5βγ2,
α6βγ2, α6β2δ, α6β3δ and ρ) with further receptor isoforms oc-
curring with high probability, or only tentatively [286, 287]. It
is beyond the scope of this Guide to discuss the pharmacology
of individual GABAA receptor isoforms in detail; such informa-
tion can be gleaned in the reviews [20, 117, 181, 206, 209, 270,
286, 287, 331] and [11, 12]. Agents that discriminate between
α-subunit isoforms are noted in the table and additional agents
that demonstrate selectivity between receptor isoforms, for exam-
ple via β-subunit selectivity, are indicated in the text below. The
distinctive agonist and antagonist pharmacology of ρ receptors
is summarised in the table and additional aspects are reviewed in
[60, 182, 274, 406].
Nomenclature GABAA receptor α1 subunit GABAA receptor α2 subunit
HGNC, UniProt GABRA1, P14867 GABRA2, P47869
Agonists gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site], muscimol
[GABA site], piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site],
muscimol [GABA site], piperidine-4-sulphonic acid [GABA site]
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric
modulators
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
Allosteric modulators ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9.1) [159], clonazepam (Positive)
(pKi 8.9) [309], ﬂunitrazepam [benzodiazepine site] (Positive) (pKi 8.3) [133], diazepam
[benzodiazepine site] (Positive) (pKi 7.8) [309], alprazolam [benzodiazepine site]
(Positive) (pEC50 7.4) [5], α3IA [benzodiazepine site] (Inverse agonist), α5IA
[benzodiazepine site] (Inverse agonist), DMCM [benzodiazepine site] (Inverse agonist)
ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9.1) [159], clonazepam (Positive)
(pKi 8.8) [309], ﬂunitrazepam [benzodiazepine site] (Positive) (pKi 8.3) [133],
alprazolam [benzodiazepine site] (Positive) (pEC50 7.9) [5], diazepam [benzodiazepine
site] (Positive) (pKi 7.8) [309], α3IA [benzodiazepine site] (Inverse agonist), α5IA
[benzodiazepine site] (Inverse agonist), DMCM [benzodiazepine site] (Inverse agonist)
Searchable database: http://www.guidetopharmacology.org/index.jsp GABAA receptors S137
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. British Journal of Pharmacology (2017) 174, S130–S159
(continued)
Nomenclature GABAA receptor α1 subunit GABAA receptor α2 subunit
Selective allosteric
modulators
zolpidem (Positive) (pKi 7.4–7.7) [134, 325], L838417 [benzodiazepine site]
(Antagonist), ZK93426 [benzodiazepine site] (Antagonist), indiplon [benzodiazepine
site] (Full agonist), ocinaplon [benzodiazepine site] (Full agonist)
L838417 [benzodiazepine site] (Partial agonist), TPA023 [benzodiazepine site] (Partial
agonist)
Labelled ligands [11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric
modulator, Positive), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA site]
(Agonist), [3H]zolpidem [benzodiazepine site] (Allosteric modulator, Positive)
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [208]
Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [208]
Nomenclature GABAA receptor α3 subunit GABAA receptor α4 subunit
HGNC, UniProt GABRA3, P34903 GABRA4, P48169
Agonists gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site], muscimol
[GABA site], piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site] (low efﬁcacy)
Selective agonists – isonipecotic acid [GABA site] (relatively high efﬁcacy)
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric
modulators
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
Allosteric modulators ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9) [159], clonazepam (Positive) (pKi
8.7) [309], ﬂunitrazepam [benzodiazepine site] (Positive) (pKi 7.8) [133], diazepam
[benzodiazepine site] (Positive) (pKi 7.8) [309], alprazolam [benzodiazepine site]
(Positive) (pEC50 7.2) [5], α5IA [benzodiazepine site] (Inverse agonist), DMCM
[benzodiazepine site] (Inverse agonist)
–
Selective allosteric
modulators
α3IA [benzodiazepine site] (higher afﬁnity), L838417 [benzodiazepine site] (Partial
agonist), Ro19-4603 [benzodiazepine site] (Inverse agonist), TP003 [benzodiazepine site]
(Partial agonist), TPA023 [benzodiazepine site] (Partial agonist)
Ro15-4513 [benzodiazepine site] (Full agonist), bretazenil [benzodiazepine site] (Full
agonist)
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Nomenclature GABAA receptor α3 subunit GABAA receptor α4 subunit
Labelled ligands [11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist)
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Partial agonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]Ro154513 [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol
[GABA site] (Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [208]
diazepam and ﬂunitrazepam are not active at this subunit. Zn2+ is an endogenous
allosteric regulator and causes potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a δ or γ subunit causes a modest,
or pronounced, reduction in inhibitory potency, respectively [208]. [3H]Ro154513
selectively labels α4-subunit-containing receptors in the presence of a saturating
concentration of a ’classical’ benzodiazepine (e.g. diazepam)
Nomenclature GABAA receptor α5 subunit GABAA receptor α6 subunit
HGNC, UniProt GABRA5, P31644 GABRA6, Q16445
Agonists gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site], muscimol
[GABA site], piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site] (low efﬁcacy)
Selective agonists – isonipecotic acid [GABA site] (relatively high efﬁcacy)
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric
modulators
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
Allosteric modulators ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9.2) [159], ﬂunitrazepam
[benzodiazepine site] (Positive) (pKi 8.3) [137], alprazolam [benzodiazepine site]
(Positive) (pEC50 8) [5], α3IA [benzodiazepine site] (Inverse agonist), DMCM
[benzodiazepine site] (Inverse agonist)
ﬂumazenil [benzodiazepine site] (Partial agonist) (pKi 6.8) [159], bretazenil
[benzodiazepine site] (Full agonist)
Selective allosteric
modulators
α5IA [benzodiazepine site] (Inverse agonist), L655708 [benzodiazepine site] (Inverse
agonist), L838417 [benzodiazepine site] (Partial agonist), MRK016 [benzodiazepine site]
(Inverse agonist), RO4938581 [benzodiazepine site] (Inverse agonist), RY024
[benzodiazepine site] (Inverse agonist)
Ro15-4513 [benzodiazepine site] (Full agonist)
Searchable database: http://www.guidetopharmacology.org/index.jsp GABAA receptors S139
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. British Journal of Pharmacology (2017) 174, S130–S159
(continued)
Nomenclature GABAA receptor α5 subunit GABAA receptor α6 subunit
Labelled ligands [3H]RY80 [benzodiazepine site] (Selective Binding) (pKd 9.2) [335] – Rat,
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]L655708 [benzodiazepine site] (Allosteric modulator,
Inverse agonist), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric modulator, Full
agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA site] (Agonist)
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Partial agonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]Ro154513 [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [208]
diazepam and ﬂunitrazepam are not active at this subunit. Zn2+ is an endogenous
allosteric regulator and causes potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a δ or γ subunit causes a modest,
or pronounced, reduction in inhibitory potency, respectively [208]. [3H]Ro154513
selectively labels α6-subunit-containing receptors in the presence of a saturating
concentration of a ’classical’ benzodiazepine (e.g. diazepam)
Nomenclature GABAA receptor β1 subunit GABAA receptor β2 subunit GABAA receptor β3 subunit
HGNC, UniProt GABRB1, P18505 GABRB2, P47870 GABRB3, P28472
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Allosteric modulators – – etazolate (Binding) (pIC50 5.5) [404]
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a δ or
γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively [208]
Nomenclature GABAA receptor γ1 subunit GABAA receptor γ2 subunit GABAA receptor γ3 subunit
HGNC, UniProt GABRG1, Q8N1C3 GABRG2, P18507 GABRG3, Q99928
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a δ or
γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively [208]
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Nomenclature GABAA receptor δ subunit GABAA receptor  subunit GABAA receptor θ subunit GABAA receptor π subunit
HGNC, UniProt GABRD, O14764 GABRE, P78334 GABRQ, Q9UN88 GABRP, O00591
Selective agonists gaboxadol [GABA site] – – –
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments Zn2+ is an endogenous allosteric regulator and causes
potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a δ
or γ subunit causes a modest, or pronounced, reduction
in inhibitory potency, respectively
– – –
Nomenclature GABAA receptor ρ1 subunit GABAA receptor ρ2 subunit GABAA receptor ρ3 subunit
HGNC, UniProt GABRR1, P24046 GABRR2, P28476 GABRR3, A8MPY1
Agonists isoguvacine [GABA site] (Partial agonist),
muscimol [GABA site] (Partial agonist)
isoguvacine [GABA site] (Partial agonist), muscimol
[GABA site] (Partial agonist)
isoguvacine [GABA site] (Partial agonist), muscimol [GABA site]
(Partial agonist)
Selective agonists (±)-cis-2-CAMP [GABA site], 5-Me-IAA [GABA
site]
(±)-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site] (±)-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site]
Antagonists gaboxadol [GABA site], isonipecotic acid
[GABA site], piperidine-4-sulphonic acid [GABA
site]
gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
Selective antagonists cis-3-ACPBPA [GABA site], trans-3-ACPBPA
[GABA site], TPMPA [GABA site], aza-THIP
[GABA site]
cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site],
TPMPA [GABA site], aza-THIP [GABA site]
cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site], TPMPA
[GABA site], aza-THIP [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments bicuculline is not active at this subunit bicuculline is not active at this subunit bicuculline is not active at this subunit
Comments: The potency and efﬁcacy of many GABA agonists
vary between GABAA receptor isoforms [117, 188, 209]. For ex-
ample, gaboxadol is a partial agonist at receptors with the subunit
composition α4β3γ2, but elicits currents in excess of those evoked
by GABA at the α4β3δ receptor where GABA itself is a low efﬁcacy
agonist [32, 43]. The antagonists bicuculline and gabazine differ
in their ability to suppress spontaneous openings of the GABAA re-
ceptor, the former being more effective [359]. The presence of the
γ subunit within the heterotrimeric complex reduces the potency
and efﬁcacy of agonists [347]. The GABAA receptor contains dis-
tinct allosteric sites that bind barbiturates and endogenous (e.g.,
5α-pregnan-3α-ol-20-one) and synthetic (e.g., alphaxalone) neu-
roactive steroids in a diastereo- or enantio-selective manner [28,
143, 154, 368]. Picrotoxinin and TBPS act at an allosteric site
within the chloride channel pore to negatively regulate channel
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activity; negative allosteric regulation by γ-butyrolactone deriva-
tives also involves the picrotoxinin site, whereas positive allosteric
regulation by such compounds is proposed to occur at a distinct
locus. Many intravenous (e.g., etomidate, propofol) and inhala-
tional (e.g., halothane, isoﬂurane) anaesthetics and alcohols also
exert a regulatory inﬂuence upon GABAA receptor activity [38,
285]. Speciﬁc amino acid residues within GABAA receptor α- and
β-subunits that inﬂuence allosteric regulation by anaesthetic and
non-anaesthetic compounds have been identiﬁed [141, 154]. Pho-
toafﬁnity labelling of distinct amino acid residues within puriﬁed
GABAA receptors by the etomidate derivative, [
3H]azietomidate,
has also been demonstrated [221] and this binding subject to
positive allosteric regulation by anaesthetic steroids [220]. An
array of natural products including ﬂavonoid and terpenoid
compounds exert varied actions at GABAA receptors (reviewed in
detail in [181]).
In addition to the agents listed in the table, modulators of GABAA
receptor activity that exhibit subunit dependent activity include:
salicylidene salicylhydrazide [negative allosteric modulator selec-
tive for β1- versus β2-, or β3-subunit-containing receptors [360]];
fragrent dioxane derivatives [positive allosteric modulators selec-
tive for β1- versus β2-, or β3-subunit-containing receptors [328]];
loreclezole, etomidate, tracazolate, mefenamic acid, etifoxine,
stiripentol, valerenic acid amide [positive allosteric modulators
with selectivity for β2/β3- over β1-subunit-containing receptors
[112, 198, 206]]; tracazolate [intrinsic efﬁcacy, i.e., potentiation,
or inhibition, is dependent upon the identity of the γ1-3-, δ-, or
-subunit co-assembed with α1- and β1-subunits [358]]; amiloride
[selective blockade of receptors containing an α6-subunit [115]];
furosemide [selective blockade of receptors containing an α6-
subunit co-assembled with β2/β3-, but not β1-subunit [206]]; La3+
[potentiates responses mediated by α1β3γ2L receptors, weakly in-
hibits α6β3γ2L receptors, and strongly blocks α6β3δ and α4β3δ
receptors [43, 321]]; ethanol [selectively potentiates responses
mediated by α4β3δ and α6β3δ receptors versus receptors in which
β2 replaces β3, or γ replaces δ [378], but see also [205]]; DS1
and DS2 [selectively potentiate responses mediated by δ-subunit-
containing receptors [374]]. It should be noted that the appar-
ent selectivity of some positive allosteric modulators (e.g., neuros-
teroids such as 5α-pregnan-3α-ol-20-one for δ-subunit-containing
receptors (e.g., α1β3δ) may be a consequence of the unusually low
efﬁcacy of GABA at this receptor isoform [27, 32].
Further reading on GABAA receptors
Braat, S et al. (2015) The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disor-
ders. Neuron 86: 1119-30 [PMID:26050032]
Calvo, DJ et al. (2016) Dynamic Regulation of the GABAA Receptor Function by RedoxMechanisms.
Mol Pharmacol 90: 326-33 [PMID:27439531]
Locci, A et al. (2017) Neurosteroid biosynthesis downregulation and changes in GABAA receptor
subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment.
Br J Pharmacol [PMID:28456011]
Mele, M et al. (2016) Role of GABAA R trafﬁcking in the plasticity of inhibitory synapses. J Neu-
rochem 139: 997-1018 [PMID:27424566]
Olsen, RW et al. (2008) International Union of Pharmacology. LXX. Subtypes of gamma-
aminobutyric acid(A) receptors: classiﬁcation on the basis of subunit composition, pharma-
cology, and function. Update. Pharmacol Rev 60: 243-60 [PMID:18790874]
Glycine receptors
Ligand-gated ion channels → Glycine receptors
Overview: The inhibitory glycine receptor (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Glycine Re-
ceptors) is a member of the Cys-loop superfamily of transmitter-
gated ion channels that includes the zinc activated channels,
GABAA, nicotinic acetylcholine and 5-HT3 receptors [233]. The
receptor is expressed either as a homo-pentamer of α subunits, or
a complex now thought to harbour 2α and 3β subunits [30, 129],
that contain an intrinsic anion channel. Four differentially ex-
pressed isoforms of the α-subunit (α1-α4) and one variant of the
β-subunit (β1, GLRB, P48167) have been identiﬁed by genomic
and cDNA cloning. Further diversity originates from alternative
splicing of the primary gene transcripts for α1 (α1INS and α1del),
α2 (α2A and α2B), α3 (α3S and α3L) and β (β7) subunits and
by mRNA editing of the α2 and α3 subunit [103, 249, 284]. Both
α2 splicing and α3 mRNA editing can produce subunits (i.e., α2B
and α3P185L) with enhanced agonist sensitivity. Predominantly,
the mature form of the receptor contains α1 (or α3) and β sub-
units while the immature form is mostly composed of only α2
subunits. RNA transcripts encoding the α4-subunit have not been
detected in adult humans. The N-terminal domain of the α-
subunit contains both the agonist and strychnine binding sites
that consist of several discontinuous regions of amino acids. In-
clusion of the β-subunit in the pentameric glycine receptor con-
tributes to agonist binding, reduces single channel conductance
and alters pharmacology. The β-subunit also anchors the recep-
tor, via an amphipathic sequence within the large intracellular
loop region, to gephyrin. The latter is a cytoskeletal attachment
protein that binds to a number of subsynaptic proteins involved
in cytoskeletal structure and thus clusters and anchors hetero-
oligomeric receptors to the synapse [201, 204, 268]. G-protein βγ
subunits enhance the open state probability of native and recom-
binant glycine receptors by association with domains within the
large intracellular loop [397, 398]. Intracellular chloride concen-
tration modulates the kinetics of native and recombinant glycine
receptors [304]. Intracellular Ca2+ appears to increase native and
recombinant glycine receptor afﬁnity, prolonging channel open
events, by a mechanism that does not involve phosphorylation
[118].
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Nomenclature glycine receptor α1 subunit glycine receptor α2 subunit glycine receptor α3 subunit glycine receptor α4
subunit (pseudogene
in humans)
HGNC, UniProt GLRA1, P23415 GLRA2, P23416 GLRA3, O75311 GLRA4, Q5JXX5
Selective agonists
(potency order)
glycine > β-alanine > taurine glycine > β-alanine > taurine glycine > β-alanine > taurine –
Selective antagonists ginkgolide X (pIC50 6.1), pregnenolone sulphate
(pKi 5.7), nifedipine (pIC50 5.5), bilobalide (pIC50
4.7), tropisetron (pKi 4.1), colchicine (pIC50 3.5),
HU-308 (weak inhibition), PMBA, strychnine
HU-210 (pIC50 7), WIN55212-2 (pIC50 6.7), HU-308
(pIC50 6), ginkgolide X (pIC50 5.6),
pregnenolone sulphate (pKi 5.3), bilobalide (pIC50
5.1), tropisetron (pKi 4.9), colchicine (pIC50 4.2),
5,7-dichlorokynurenic acid (pIC50 3.7), PMBA,
strychnine
HU-210 (pIC50 7.3), HU-308 (pIC50
7), WIN55212-2 (pIC50 7),
(12E,20Z,18S)-8-hydroxyvariabilin
(pIC50 5.2), nifedipine (pIC50 4.5),
strychnine
–
Channel blockers ginkgolide B (pIC50 5.1–6.2), cyanotriphenylborate
(pIC50 5.9) [316], picrotin (pIC50 5.3), picrotoxinin
(pIC50 5.3), picrotoxin (pIC50 5.2)
picrotoxinin (pIC50 6.4), picrotoxin (pIC50 5.6),
ginkgolide B (pIC50 4.9–5.4), picrotin (pIC50 4.9),
cyanotriphenylborate (pIC50 >4.7) [316]
picrotoxinin (pIC50 6.4), ginkgolide B
(pIC50 5.7), picrotin (pIC50 5.2),
picrotoxin (block is weaker when β
subunit is co-expressed)
–
Endogenous allosteric
modulators
Zn2+ (Potentiation) (pEC50 7.4), Cu2+ (Inhibition)
(pIC50 4.8–5.4), Zn2+ (Inhibition) (pIC50 4.8),
Extracellular H+ (Inhibition)
Zn2+ (Potentiation) (pEC50 6.3), Cu2+ (Inhibition)
(pIC50 4.8), Zn2+ (Inhibition) (pIC50 3.4)
Cu2+ (Inhibition) (pIC50 5), Zn2+
(Inhibition) (pIC50 3.8)
–
Selective allosteric
modulators
anandamide (Potentiation) (pEC50 7.4), HU-210
(Potentiation) (pEC50 6.6),
9-tetrahydrocannabinol (Potentiation) (pEC50
∼5.5)
9-tetrahydrocannabinol (Potentiation) (pEC50 ∼6) 9-tetrahydrocannabinol
(Potentiation) (pEC50 ∼5.3)
–
Labelled ligands [3H]strychnine (Antagonist) [3H]strychnine (Antagonist) [3H]strychnine (Antagonist) –
Functional Characteristics γ = 86 pS (main state); (+ β = 44 pS) γ = 111 pS (main state); (+ β = 54 pS) γ = 105 pS (main state); (+ β = 48) –
Nomenclature glycine receptor β subunit
HGNC, UniProt GLRB, P48167
Selective antagonists nifedipine (when co-expressed with the α1 subunit) (pIC50 5.9), pregnenolone sulphate (when co-expressed with the α1 subunit) (pKi 5.6), tropisetron (when co-expressed with
the α2 subunit) (pKi 5.3), pregnenolone sulphate (when co-expressed with the α2 subunit) (pKi 5), nifedipine (when co-expressed with the α3 subunit) (pIC50 4.9), bilobalide
(when co-expressed with the α2 subunit) (pIC50 4.3), bilobalide (when co-expressed with the α1 subunit) (pIC50 3.7), ginkgolide X (when co-expressed with the α1 subunit)
(pIC50 >3.5), ginkgolide X (when co-expressed with the α2 subunit) (pIC50 >3.5)
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(continued)
Nomenclature glycine receptor β subunit
Channel blockers ginkgolide B (when co-expressed with the α2 subunit) (pIC50 6.1–6.9), ginkgolide B (when co-expressed with the α1 subunit) (pIC50 5.6–6.7), ginkgolide B (when co-expressed
with the α3 subunit) (pIC50 6.3), cyanotriphenylborate (when co-expressed with the human α1 subunit) (pIC50 5.6) [316] – Rat, cyanotriphenylborate (when co-expressed with
the human α2 subunit) (pIC50 5.1) [316] – Rat, picrotoxinin (when co-expressed with the α3 subunit) (pIC50 5.1), picrotin (when co-expressed with the α1 subunit) (pIC50 4.6),
picrotin (when co-expressed with the α3 subunit) (pIC50 4.6), picrotoxinin (when co-expressed with the α1 subunit) (pIC50 4.6), picrotoxin (when co-expressed with the α2
subunit) (pIC50 4.5), picrotoxin (when co-expressed with the α1 subunit) (pIC50 3.7)
Endogenous allosteric
modulators
Zn2+ (Inhibition) (pIC50 4.9), Zn2+ (Inhibition) (pIC50 3.7)
Comments Ligand interaction data for hetero-oligomer receptors containing the β subunit are also listed under the α subunit
Comments: Data in the table refer to homo-oligomeric assem-
blies of the α-subunit, signiﬁcant changes introduced by co-
expression of the β1 subunit are indicated in parenthesis. Not all
glycine receptor ligands are listed within the table, but some that
may be useful in distinguishing between glycine receptor isoforms
are indicated (see detailed view pages for each subunit: α1, α2,
α3, α4, β ). Pregnenolone sulphate, tropisetron and colchicine,
for example, although not selective antagonists of glycine recep-
tors, are included for this purpose. Strychnine is a potent and
selective competitive glycine receptor antagonist with afﬁnities in
the range 5–15 nM. RU5135 demonstrates comparable potency,
but additionally blocks GABAA receptors. There are conﬂicting re-
ports concerning the ability of cannabinoids to inhibit [228], or
potentiate and at high concentrations activate [3, 83, 140, 389,
394] glycine receptors. Nonetheless, cannabinoid analogues may
hold promise in distinguishing between glycine receptor subtypes
[394]. In addition, potentiation of glycine receptor activity by
cannabinoids has been claimed to contribute to cannabis-induced
analgesia relying on Ser296/307 (α1/α3) in M3 [389]. Several ana-
logues of muscimol and piperidine act as agonists and antago-
nists of both glycine and GABAA receptors. Picrotoxin acts as
an allosteric inhibitor that appears to bind within the pore, and
shows strong selectivity towards homomeric receptors. While its
components, picrotoxinin and picrotin, have equal potencies at
α1 receptors, their potencies at α2 and α3 receptors differ mod-
estly and may allow some distinction between different recep-
tor types [395]. Binding of picrotoxin within the pore has been
demonstrated in the crystal structure of the related C. elegans
GluCl Cys-loop receptor [144]. In addition to the compounds
listed in the table, numerous agents act as allosteric regulators of
glycine receptors (comprehensively reviewed in [215, 234, 381,
399]). Zn2+ acts through distinct binding sites of high- and low-
afﬁnity to allosterically enhance channel function at low (<10
μM) concentrations and inhibits responses at higher concentra-
tions in a subunit selective manner [258]. The effect of Zn2+ is
somewhat mimicked by Ni2+. Endogenous Zn2+ is essential for
normal glycinergic neurotransmission mediated by α1 subunit-
containing receptors [147]. Elevation of intracellular Ca2+ pro-
duces fast potentiation of glycine receptor-mediated responses.
Dideoxyforskolin (4 μM) and tamoxifen (0.2–5 μM) both poten-
tiate responses to low glycine concentrations (15 μM), but act
as inhibitors at higher glycine concentrations (100 μM). Addi-
tional modulatory agents that enhance glycine receptor function
include inhalational, and several intravenous general anaesthet-
ics (e.g. minaxolone, propofol and pentobarbitone) and certain
neurosteroids. Ethanol and higher order n-alcohols also enhance
glycine receptor function although whether this occurs by a di-
rect allosteric action at the receptor [245], or through βγ subunits
[396] is debated. Recent crystal structures of the bacterial homo-
logue, GLIC, have identiﬁed transmembrane binding pockets for
both anaesthetics [282] and alcohols [156]. Solvents inhaled as
drugs of abuse (e.g. toluene, 1-1-1-trichloroethane) may act at sites
that overlap with those recognising alcohols and volatile anaes-
thetics to produce potentiation of glycine receptor function. The
function of glycine receptors formed as homomeric complexes
of α1 or α2 subunits, or hetero-oligomers of α1/β or α2/β sub-
units, is differentially affected by the 5-HT3 receptor antagonist
tropisetron (ICS 205-930) which may evoke potentiation (which
may occur within the femtomolar range at the homomeric glycine
α1 receptor), or inhibition, depending upon the subunit compo-
sition of the receptor and the concentrations of the modulator
and glycine employed. Potentiation and inhibition by tropeines
involves different binding modes [238]. Additional tropeines, in-
cluding atropine, modulate glycine receptor activity.
Further reading on Glycine receptors
Betz, H et al. (2006) Glycine receptors: recent insights into their structural organization and func-
tional diversity. J Neurochem 97: 1600-10 [PMID:16805771]
Burgos, CF et al. (2016) Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors.
Mol Pharmacol 90: 318-25 [PMID:27401877]
Dutertre, S et al. (2012) Inhibitory glycine receptors: an update. J Biol Chem 287: 40216-23
[PMID:23038260]
Lynch, JW. (2004)Molecular structure and function of the glycine receptor chloride channel. Physiol
Rev 84: 1051-95 [PMID:15383648]
Perkins, DI et al. (2010) Molecular targets and mechanisms for ethanol action in glycine receptors.
Pharmacol Ther 127: 53-65 [PMID:20399807]
Yevenes, GE et al. (2011) Allosteric modulation of glycine receptors. Br J Pharmacol 164: 224-36
[PMID:21557733]
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Ionotropic glutamate receptors
Ligand-gated ion channels → Ionotropic glutamate receptors
Overview: The ionotropic glutamate receptors comprise mem-
bers of the NMDA (N-methyl-D-aspartate), AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazoleproprionic acid) and kainate
receptor classes, named originally according to their preferred,
synthetic, agonist [86, 226, 365]. Receptor heterogeneity within
each class arises from the homo-oligomeric, or hetero-oligomeric,
assembly of distinct subunits into cation-selective tetramers.
Each subunit of the tetrameric complex comprises an extra-
cellular amino terminal domain (ATD), an extracellular ligand
binding domain (LBD), three transmembrane domains composed
of three membrane spans (M1, M3 and M4), a channel lining
re-entrant ‘p-loop’ (M2) located between M1 and M3 and an in-
tracellular carboxy- terminal domain (CTD) [184, 211, 246, 271,
365]. The X-ray structure of a homomeric ionotropic glutamate
receptor (GluA2 – see below) has recently been solved at 3.6Å
resolution [340] and although providing the most complete struc-
tural information current available may not representative of the
subunit arrangement of, for example, the heteromeric NMDA re-
ceptors [187]. It is beyond the scope of this supplement to discuss
the pharmacology of individual ionotropic glutamate receptor
isoforms in detail; such information can be gleaned from [62,
74, 86, 106, 171, 177, 195, 288, 289, 290, 365, 388]. Agents that
discriminate between subunit isoforms are, where appropriate,
noted in the tables and additional compounds that distinguish
between receptor isoforms are indicated in the text below.
The classiﬁcation of glutamate receptor subunits has been re-addressed by NC-IUPHAR [71]. The scheme developed recommends a nomenclature for ionotropic glutamate receptor subunits
that is adopted here.
AMPA and Kainate receptors
AMPA receptors assemble as homomers, or heteromers, that
may be drawn from GluA1, GluA2, GluA3 and GluA4 and
GluD1, GluD2, GluK1, GluK2, GluK3, GluK4 and GluK5 sub-
units. Transmembrane AMPA receptor regulatory proteins (TARPs)
of class I (i.e. γ2, γ3, γ4 and γ8) act, with variable stoichiome-
try, as auxiliary subunits to AMPA receptors and inﬂuence their
trafﬁcking, single channel conductance gating and pharmacology
(reviewed in [108, 165, 260, 362]). Functional kainate receptors
can be expressed as homomers of GluK1, GluK2 or GluK3 sub-
units. GluK1-3 subunits are also capable of assembling into het-
erotetramers (e.g. GluK1/K2; [218, 300, 303]). Two additional
kainate receptor subunits, GluK4 and GluK5, when expressed in-
dividually, form high afﬁnity binding sites for kainate, but lack
function, but can form heteromers when expressed with GluK1-3
subunits (e.g. GluK2/K5; reviewed in [171, 300, 303]). Kainate
receptors may also exhibit ‘metabotropic’ functions [218, 312].
As found for AMPA receptors, kainate receptors are modulated by
auxiliary subunits (Neto proteins, [219, 300]). An important func-
tion difference between AMPA and kainate receptors is that the lat-
ter require extracellular Na+ and Cl- for their activation [40, 306].
RNA encoding the GluA2 subunit undergoes extensive RNA edit-
ing in which the codon encoding a p-loop glutamine residue (Q) is
converted to one encoding arginine (R). This Q/R site strongly in-
ﬂuences the biophysical properties of the receptor. Recombinant
AMPA receptors lacking RNA edited GluA2 subunits are: (1) per-
meable to Ca2+; (2) blocked by intracellular polyamines at depo-
larized potentials causing inward rectiﬁcation (the latter being re-
duced by TARPs); (3) blocked by extracellular argiotoxin and Joro
spider toxins and (4) demonstrate higher channel conductances
than receptors containing the edited form of GluA2 [163, 326].
GluK1 and GluK2, but not other kainate receptor subunits, are
similarly edited and broadly similar functional characteristics ap-
ply to kainate receptors lacking either an RNA edited GluK1, or
GluK2, subunit [218, 300]. Native AMPA and kainate receptors
displaying differential channel conductances, Ca2+ permeabilites
and sensitivity to block by intracellular polyamines have been
identiﬁed [73, 163, 224]. GluA1-4 can exist as two variants gener-
ated by alternative splicing (termed ‘ﬂip’ and ‘ﬂop’) that differ in
their desensitization kinetics and their desensitization in the pres-
ence of cyclothiazide which stabilises the nondesensitized state.
TARPs also stabilise the non-desensitized conformation of AMPA
receptors and facilitate the action of cyclothiazide [260]. Splice
variants of GluK1-3 also exist which affects their trafﬁcking [218,
300].
Nomenclature GluA1 GluA2 GluA3 GluA4
HGNC, UniProt GRIA1, P42261 GRIA2, P42262 GRIA3, P42263 GRIA4, P48058
Agonists (S)-5-ﬂuorowillardiine, AMPA (S)-5-ﬂuorowillardiine, AMPA (S)-5-ﬂuorowillardiine, AMPA (S)-5-ﬂuorowillardiine, AMPA
Selective
antagonists
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
Channel blockers extracellular argiotoxin, extracellular
joro toxin (selective for channels lacking
GluA2)
extracellular argiotoxin extracellular argiotoxin, extracellular
joro toxin (selective for channels lacking
GluA2)
extracellular argiotoxin, extracellular
joro toxin (selective for channels lacking
GluA2)
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(continued)
Nomenclature GluA1 GluA2 GluA3 GluA4
Allosteric
modulators
LY392098 (Positive) (pEC50 5.8) [261],
LY404187 (Positive) (pEC50 5.2) [261],
cyclothiazide (Positive) (pEC50 4.7) [261],
CX516 (Positive), CX546 (Positive),
IDRA-21 (Positive), LY503430 (Positive),
S18986 (Positive), aniracetam (Positive),
piracetam (Positive)
LY404187 (Positive) (pEC50 6.8) [261],
LY392098 (Positive) (pEC50 6.7) [261],
cyclothiazide (Positive) (pEC50 5.7) [261],
CX516 (Positive), CX546 (Positive), IDRA-21
(Positive), LY503430 (Positive), S18986
(Positive), aniracetam (Positive), piracetam
(Positive)
LY404187 (Positive) (pEC50 5.8) [261],
LY392098 (Positive) (pEC50 5.7) [261],
cyclothiazide (Positive) (pEC50 4.9) [261],
CX516 (Positive), CX546 (Positive), IDRA-21
(Positive), LY503430 (Positive), S18986
(Positive), aniracetam (Positive), piracetam
(Positive)
LY392098 (Positive) (pEC50 6.7) [261],
LY404187 (Positive) (pEC50 6.7) [261],
cyclothiazide (Positive) (pEC50 5.4) [261],
CX516 (Positive), CX546 (Positive),
IDRA-21 (Positive), LY503430 (Positive),
S18986 (Positive), aniracetam (Positive),
piracetam (Positive)
Labelled ligands [3H]AMPA (Agonist), [3H]CNQX
(Antagonist)
[3H]AMPA (Agonist), [3H]CNQX
(Antagonist)
[3H]AMPA, [3H]CNQX [3H]AMPA (Agonist), [3H]CNQX
Comments Also blocked by intracellular polyamines. Also blocked by intracellular polyamines. Also blocked by intracellular polyamines Also blocked by intracellular polyamines
Nomenclature GluD1 GluD2
HGNC, UniProt GRID1, Q9ULK0 GRID2, O43424
Nomenclature GluK1 GluK2 GluK3 GluK4 GluK5
HGNC, UniProt GRIK1, P39086 GRIK2, Q13002 GRIK3, Q13003 GRIK4, Q16099 GRIK5, Q16478
Endogenous agonists – – –
Agonists dysiherbaine [320] – Rat, SYM2081
[296], kainate [336], (S)-4-AHCP,
(S)-5-iodowillardiine,
8-deoxy-neodysiherbaine, ATPA,
domoic acid
dysiherbaine [320] – Rat,
domoic acid [50],
SYM2081 [413] – Rat,
kainate [50, 336]
SYM2081 [318] – Rat,
kainate (low potency)
[318] – Rat, dysiherbaine
SYM2081, domoic acid, dysiherbaine,
kainate
SYM2081, domoic acid,
dysiherbaine, kainate
Selective agonists LY339434 [342] –
Selective antagonists 2,4-epi-neodysiherbaine, ACET,
LY382884, LY466195, MSVIII-19,
NS3763 (non-competitive), UBP302,
UBP310
2,4-epi-neo
dysiherbaine
– – –
Allosteric modulators concanavalin A (Positive) concanavalin A (Positive) – – –
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Nomenclature GluK1 GluK2 GluK3 GluK4 GluK5
Labelled ligands [3H]UBP310 (Antagonist) (pKd 7.7)
[13], [3H]SYM2081 (Agonist),
[3H]kainate (Agonist)
[3H]kainate (Agonist)
[407] – Rat,
[3H]SYM2081 (Agonist)
[3H]UBP310 (Antagonist)
(pKd 6.3) [13],
[3H]SYM2081 (Agonist),
[3H]kainate (Agonist)
[3H]SYM2081 (Agonist), [3H]kainate
(Agonist)
[3H]SYM2081 (Agonist),
[3H]kainate (Agonist)
Comments – Intracellular polyamines
are subtype selective
channel blockers (GluK3
 GluK2)
domoic acid and
concanavalin A are
inactive at the GluK3
subunit. Intracellular
polyamines are subtype
selective channel blockers
(GluK3  GluK2)
– –
NMDA receptors
NMDA receptors assemble as obligate heteromers that may be
drawn from GluN1, GluN2, GluN3 and GluN4 subunits. Alterna-
tive splicing can generate eight isoforms of GluN1 with differing
pharmacological properties. Various splice variants of GluN2B,
2C, 2D and GluN3A have also been reported. Activation of
NMDA receptors containing GluN1 and GluN2 subunits requires
the binding of two agonists, glutamate to the S1 and S2 regions of
the GluN2 subunit and glycine to S1 and S2 regions of the GluN1
subunit [63, 105]. The minimal requirement for efﬁcient func-
tional expression of NMDA receptors in vitro is a di-heteromeric
assembly of GluN1 and at least one GluN2 subunit variant, as a
dimer of heterodimers arrangement in the extracellular domain
[119, 187, 246]. However, more complex tri-heteromeric assem-
blies, incorporatingmultiple subtypes of GluN2 subunit, or GluN3
subunits, can be generatedin vitro and occurin vivo. The NMDA re-
ceptor channel commonly has a high relative permeability to Ca2+
and is blocked, in a voltage-dependent manner, byMg2+ such that
at resting potentials the response is substantially inhibited.
Nomenclature GluN1 GluN2A GluN2B GluN2C GluN2D
HGNC, UniProt GRIN1, Q05586 GRIN2A, Q12879 GRIN2B, Q13224 GRIN2C, Q14957 GRIN2D, O15399
Endogenous
agonists
D-aspartic acid [glutamate site],
D-serine [glycine site],
L-aspartic acid [glutamate site],
glycine [glycine site]
D-aspartic acid [glutamate site] (GluN2D > GluN2C = GluN2B >
GluN2A), D-serine [glycine site] (GluN2D > GluN2C > GluN2B >
GluN2A), L-aspartic acid [glutamate site] (GluN2D = GluN2B >
GluN2C = GluN2A), glycine [glycine site] (GluN2D > GluN2C >
GluN2B > GluN2A)
D-aspartic acid [glutamate site] (GluN2D > GluN2C = GluN2B >
GluN2A), D-serine [glycine site] (GluN2D > GluN2C > GluN2B >
GluN2A), L-aspartic acid [glutamate site] (GluN2D = GluN2B >
GluN2C = GluN2A), glycine [glycine site] (GluN2D > GluN2C >
GluN2B > GluN2A)
Agonists (+)-HA966 [glycine site] (Partial
agonist), (RS)-(tetrazol-5-yl)glycine
[glutamate site], NMDA
[glutamate site],
homoquinolinic acid [glutamate
site] (Partial agonist)
(+)-HA966 [glycine site] (Partial agonist), (RS)-(tetrazol-5-yl)glycine
[glutamate site] (GluN2D > GluN2C = GluN2B > GluN2A), NMDA
[glutamate site] (GluN2D > GluN2C > GluN2B > GluN2A),
homoquinolinic acid [glutamate site] (GluN2B ≥ GluN2A ≥ GluN2D
> GluN2C; partial agonist at GluN2A and GluN2C)
(RS)-(tetrazol-5-yl)glycine [glutamate site] (GluN2D > GluN2C =
GluN2B > GluN2A), NMDA [glutamate site] (GluN2D > GluN2C >
GluN2B > GluN2A), homoquinolinic acid [glutamate site] (GluN2B
≥ GluN2A ≥ GluN2D > GluN2C; partial agonist at GluN2A and
GluN2C)
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Nomenclature GluN1 GluN2A GluN2B GluN2C GluN2D
Selective
antagonists
L701324 [glycine site] (pIC50 8.7)
[210] – Rat, GV196771A [glycine
site] (pKi 8.1–8.4) [67] – Rat,
L689560 [glycine site] (pIC50 8.1)
[217] – Rat,
5,7-dichlorokynurenic acid
[glycine site]
5,7-dichlorokynurenic acid [glycine site], CGP37849 [glutamate site],
GV196771A [glycine site], L689560 [glycine site], L701324 [glycine
site], LY233053 [glutamate site], NVP-AAM077 [glutamate site]
(GluN2A > GluN2B (human), but weakly selective for rat GluN2A
versus GluN2B) [14, 110, 116, 273], UBP141 [glutamate site]
(GluN2D ≥ GluN2C > GluN2A ≥ GluN2B) [266], conantokin-G
[glutamate site] (GluN2B > GluN2D = GluN2C = GluN2A), d-AP5
[glutamate site], d-CCPene [glutamate site] (GluN2A = GluN2B >
GluN2C = GluN2D), selfotel [glutamate site]
5,7-dichlorokynurenic acid [glycine site], CGP37849 [glutamate site],
GV196771A [glycine site], L689560 [glycine site], L701324 [glycine
site], LY233053 [glutamate site], UBP141 [glutamate site] (GluN2D ≥
GluN2C > GluN2A ≥ GluN2B) [266], conantokin-G [glutamate site]
(GluN2B > GluN2D = GluN2C = GluN2A), d-AP5 [glutamate site],
d-CCPene [glutamate site] (GluN2A = GluN2B > GluN2C =
GluN2D), selfotel [glutamate site]
Channel blockers – Mg2+ (GluN2A = GluN2B > GluN2C = GluN2D),
N1-dansyl-spermine (GluN2A = GluN2B  GluN2C = GluN2D),
amantidine (GluN2C = GluN2D ≥ GluN2B ≥ GluN2A), dizocilpine,
ketamine, phencyclidine
phencyclidine (pIC50 7.1) [96], ketamine (pIC50 6.2) [96],
amantidine (GluN2C = GluN2D ≥ GluN2B ≥ GluN2A) (pIC50 4.7)
[96], Mg2+ (GluN2A = GluN2B > GluN2C = GluN2D),
N1-dansyl-spermine (GluN2A = GluN2B  GluN2C = GluN2D),
dizocilpine
Labelled ligands [3H]MDL105519 [glycine site]
(Antagonist) (pKd ∼8.5) [59] –
Rat, [3H]CGP39653 [glutamate
site] (Selective Antagonist),
[3H]CGP61594 [glycine site]
(Antagonist), [3H]CGS19755
[glutamate site] (Antagonist),
[3H]CPP [glutamate site] (Selective
Antagonist), [3H]L689560 [glycine
site] (Antagonist), [3H]dizocilpine
[cation channel] (Antagonist),
[3H]glycine [glycine site] (Agonist)
[3H]CGP39653 [glutamate site] (Antagonist), [3H]CGP61594
[glycine site] (Antagonist), [3H]CGS19755 [glutamate site]
(Antagonist), [3H]CPP [glutamate site] (Antagonist), [3H]L689560
[glycine site] (Antagonist), [3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine [cation channel] (Channel blocker),
[3H]glycine [glycine site] (Agonist)
[3H]CGP39653 [glutamate site] (Antagonist), [3H]CGP61594
[glycine site] (Antagonist), [3H]CGS19755 [glutamate site]
(Antagonist), [3H]CPP [glutamate site] (Antagonist), [3H]L689560
[glycine site] (Antagonist), [3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine [cation channel] (Channel blocker),
[3H]glycine [glycine site] (Agonist)
Nomenclature GluN3A GluN3B
HGNC, UniProt GRIN3A, Q8TCU5 GRIN3B, O60391
Comments See the main comments section below for information on the pharmacology of GluN3A and GluN3B subunits
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Comments: NMDA receptors
Potency orders unreferenced in the table are from [62, 96, 106,
212, 290, 365]. In addition to the glutamate and glycine bind-
ing sites documented in the table, physiologically important in-
hibitory modulatory sites exist for Mg2+, Zn2+, and protons [74,
86, 365]. Voltage-independent inhibition by Zn2+ binding with
high afﬁnity within the ATD is highly subunit selective (GluN2A
 GluN2B > GluN2C ≥ GluN2D; [290, 365]). The receptor is also
allosterically modulated, in both positive and negative directions,
by endogenous neuroactive steroids in a subunit dependent man-
ner [153, 239]. Tonic proton blockade of NMDA receptor function
is alleviated by polyamines and the inclusion of exon 5 within
GluN1 subunit splice variants, whereas the non-competitive an-
tagonists ifenprodil and traxoprodil increase the fraction of re-
ceptors blocked by protons at ambient concentration. Inclusion
of exon 5 also abolishes potentiation by polyamines and inhi-
bition by Zn2+ that occurs through binding in the ATD [364].
Ifenprodil, traxoprodil, haloperidol, felbamate and Ro 8-4304 dis-
criminate between recombinant NMDA receptors assembled from
GluN1 and either GluN2A, or GluN2B, subunits by acting as se-
lective, non-competitive, antagonists of heterooligomers incorpo-
rating GluN2B through a binding site at the ATD GluN1/GluN2B
subunit interface [187]. LY233536 is a competitive antagonist
that also displays selectivity for GluN2B over GluN2A subunit-
containing receptors. Similarly, CGP61594 is a photoafﬁnity la-
bel that interacts selectively with receptors incorporating GluN2B
versus GluN2A, GluN2D and, to a lesser extent, GluN2C sub-
units. TCN 201 and TCN 213 have recently been shown to block
GluN2A NMDA receptors selectively by a mechanism that in-
volves allosteric inhibition of glycine binding to the GluN1 site
[29, 101, 136, 248]. In addition to inﬂuencing the pharmaco-
logical proﬁle of the NMDA receptor, the identity of the GluN2
subunit co-assembled with GluN1 is an important determinant of
biophysical properties that include sensitivity to block by Mg2+,
single-channel conductance and maximal open probablity and
channel deactivation time [74, 105, 123]. Incorporation of the
GluN3A subunit into tri-heteromers containing GluN1 andGluN2
subunits is associated with decreased single-channel conductance,
reduced permeability to Ca2+ and decreased susceptibility to block
byMg2+ [52, 142]. Reduced permeability to Ca2+ has also been ob-
served following the inclusion of GluN3B in tri-heteromers. The
expression of GluN3A, or GluN3B, with GluN1 alone forms, in
Xenopus laevis oocytes, a cation channel with unique properties
that include activation by glycine (but not NMDA), lack of per-
meation by Ca2+ and resistance to blockade by Mg2+ and NMDA
receptor antagonists [56]. The function of heteromers composed
of GluN1 and GluN3A is enhanced by Zn2+, or glycine site an-
tagonists, binding to the GluN1 subunit [236]. Zn2+ also directly
activates such complexes. The co-expression of GluN1, GluN3A
and GluN3B appears to be required to form glycine-activated re-
ceptors in mammalian cell hosts [339].
AMPA and Kainate receptors
All AMPA receptors are additionally activated by kainate (and
domoic acid) with relatively low potency, (EC50 ˜100 μM). Inclu-
sion of TARPs within the receptor complex increases the potency
and maximal effect of kainate [165, 260]. AMPA is weak partial
agonist at GluK1 and at heteromeric assemblies of GluK1/GluK2,
GluK1/GluK5 and GluK2/GluK5 [171]. Quinoxalinediones such
as CNQX and NBQX show limited selectivity between AMPA and
kainate receptors. Tezampanel also has kainate (GluK1) receptor
activity as has GYKI53655 (GluK3 and GluK2/GluK3) [171]. ATPO
is a potent competitive antagonist of AMPA receptors, has a weaker
antagonist action at kainate receptors comprising GluK1 subunits,
but is devoid of activity at kainate receptors formed from GluK2
or GluK2/GluK5 subunits. The pharmacological activity of ATPO
resides with the (S)-enantiomer. ACET and UBP310 may block
GluK3, in addition to GluK1 [13, 299]. (2S,4R)-4-methylglutamate
(SYM2081) is equipotent in activating (and desensitising) GluK1
and GluK2 receptor isoforms and, via the induction of desensiti-
sation at low concentrations, has been used as a functional antag-
onist of kainate receptors. Both (2S,4R)-4-methylglutamate and
LY339434 have agonist activity at NMDA receptors. (2S,4R)-4-
methylglutamate is also an inhibitor of the glutamate transporters
EAAT1 and EAAT2.
Delta subunits
GluD1 and GluD2 comprise, on the basis of sequence homology,
an ‘orphan’ class of ionotropic glutamate receptor subunit. They
do not form a functional receptor when expressed solely, or in
combination with other ionotropic glutamate receptor subunits,
in transfected cells [403]. However, GluD2 subunits bind D-serine
and glycine and GluD2 subunits carrying the mutation A654T
form a spontaneously open channel that is closed by D-serine
[272].
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IP3 receptor
Ligand-gated ion channels → IP3 receptor
Overview: The inositol 1,4,5-trisphosphate receptors (IP3R) are ligand-gated Ca2+-release channels on intracellular Ca2+ store sites (such as the endoplasmic reticulum). They are responsible for the
mobilization of intracellular Ca2+ stores and play an important role in intracellular Ca2+ signalling in a wide variety of cell types. Three different gene products (types I–III) have been isolated, which
assemble as large tetrameric structures. IP3Rs are closely associated with certain proteins: calmodulin ( CALM1 CALM2 CALM3, P62158) and FKBP (and calcineurin via FKBP). They are phosphorylated
by PKA, PKC, PKG and CaMKII.
Nomenclature IP3R1 IP3R2 IP3R3
HGNC, UniProt ITPR1, Q14643 ITPR2, Q14571 ITPR3, Q14573
Endogenous activators cytosolic ATP (< mM range), cytosolic Ca2+ Concentration range:
¡7.5×10−4M, IP3 (endogenous; nM - μM range)
cytosolic Ca2+ (nM range), IP3 (endogenous; nM - μM range) cytosolic Ca2+ (nM range), IP3
(endogenous; nM - μM
range)
Activators adenophostin A (pharmacological; nM range),
inositol 2,4,5-trisphosphate (pharmacological; also activated by other
InsP3 analogues)
adenophostin A (pharmacological; nM range),
inositol 2,4,5-trisphosphate (pharmacological; also activated by other
InsP3 analogues)
–
Antagonists PIP2 (μM range), caffeine (mM range), decavanadate (μM range),
xestospongin C (μM range)
decavanadate (μM range) decavanadate (μM range)
Functional Characteristics Ca2+: (PBa/PK ˜6) single-channel conductance
˜70 pS (50 mM Ca2+)
Ca2+: single-channel conductance
˜70 pS (50 mM Ca2+)
˜390 pS (220 mM Cs+)
Ca2+: single-channel
conductance
˜88 pS (55 mM Ba2+)
Comments IP3 R1 is also antagonised by calmodulin at high cytosolic Ca2+
concentrations
– –
Comments: The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect.
Further reading on IP3 receptor
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Nicotinic acetylcholine receptors
Ligand-gated ion channels → Nicotinic acetylcholine receptors
Overview: Nicotinic acetylcholine receptors are members of the
Cys-loop family of transmitter-gated ion channels that includes
the GABAA, strychnine-sensitive glycine and 5-HT3 receptors [6,
257, 334, 350, 387]. All nicotinic receptors are pentamers in which
each of the ﬁve subunits contains four α-helical transmembrane
domains. Genes encoding a total of 17 subunits (α1-10, β1-4, γ, δ
and ) have been identiﬁed [185]. All subunits with the exception
of α8 (present in avian species) have been identiﬁed in mammals.
All α subunits possess two tandem cysteine residues near to the
site involved in acetylcholine binding, and subunits not named
α lack these residues [257]. The orthosteric ligand binding site is
formed by residues within at least three peptide domains on the α
subunit (principal component), and three on the adjacent subunit
(complementary component). nAChRs contain several allosteric
modulatory sites. One such site, for positive allosteric modulators
(PAMs) and allosteric agonists, has been proposed to reside within
an intrasubunit cavity between the four transmembrane domains
[124, 401]; see also [144]). The high resolution crystal structure
of the molluscan acetylcholine binding protein, a structural ho-
mologue of the extracellular binding domain of a nicotinic recep-
tor pentamer, in complex with several nicotinic receptor ligands
(e.g.[53]) and the crystal structure of the extracellular domain of
the α1 subunit bound to α-bungarotoxin at 1.94 Å resolution [82],
has revealed the orthosteric binding site in detail (reviewed in [55,
185, 315, 334]). Nicotinic receptors at the somatic neuromuscu-
lar junction of adult animals have the stoichiometry (α1)2β1δ,
whereas an extrajunctional (α1)2β1γδ receptor predominates in
embryonic and denervated skeletal muscle and other pathological
states. Other nicotinic receptors are assembled as combinations of
α(2-6) and β(2-4) subunits. For α2, α3, α4 and β2 and β4 subunits,
pairwise combinations of α and β (e.g. α3β4 and α4β2) are sufﬁ-
cient to form a functional receptor in vitro, but far more complex
isoforms may exist in vivo (reviewed in [127, 128, 257]). There
is strong evidence that the pairwise assembly of some α and β
subunits can occur with variable stoichiometry [e.g. (α4)2(β2)2 or
(α4)3(β2)2] which inﬂuences the biophysical and pharmacological
properties of the receptor [257]. α5 and β3 subunits lack function
when expressed alone, or pairwise, but participate in the forma-
tion of functional hetero-oligomeric receptors when expressed as
a third subunit with another α and β pair [e.g. α4α5αβ2, α4αβ2β3,
α5α6β2, see [257] for further examples]. The α6 subunit can form
a functional receptor when co-expressed with β4 in vitro, but more
efﬁcient expression ensues from incorporation of a third partner,
such as β3 [391]. The α7, α8, and α9 subunits form functional
homo-oligomers, but can also combine with a second subunit to
constitute a hetero-oligomeric assembly (e.g. α7β2 and α9α10).
For functional expression of the α10 subunit, co-assembly with
α9 is necessary. The latter, along with the α10 subunit, appears to
be largely conﬁned to cochlear and vestibular hair cells. Compre-
hensive listings of nicotinic receptor subunit combinations iden-
tiﬁed from recombinant expression systems, or in vivo, are given
in [257]. In addition, numerous proteins interact with nicotinic
ACh receptors modifying their assembly, trafﬁcking to and from
the cell surface, and activation by ACh (reviewed by [9, 183, 256]).
The nicotinic receptor Subcommittee of NC-IUPHAR has recom-
mended a nomenclature and classiﬁcation scheme for nicotinic
acetylcholine (nACh) receptors based on the subunit composition
of known, naturally- and/or heterologously-expressed nACh re-
ceptor subtypes [230]. Headings for this table reﬂect abbreviations
designating nACh receptor subtypes based on the predominant α
subunit contained in that receptor subtype. An asterisk following
the indicated α subunit denotes that other subunits are known to,
or may, assemble with the indicated α subunit to form the desig-
nated nACh receptor subtype(s). Where subunit stoichiometries
within a speciﬁc nACh receptor subtype are known, numbers of
a particular subunit larger than 1 are indicated by a subscript fol-
lowing the subunit (enclosed in parentheses – see also [71]).
Nomenclature nicotinic acetylcholine receptor α1
subunit
nicotinic acetylcholine receptor α2
subunit
nicotinic acetylcholine receptor α3
subunit
nicotinic acetylcholine receptor α4
subunit
HGNC, UniProt CHRNA1, P02708 CHRNA2, Q15822 CHRNA3, P32297 CHRNA4, P43681
Commonly used
antagonists
(α1)2β1γδ and (α1)2β1δ: α-bungarotoxin
> pancuronium > vecuronium >
rocuronium > tubocurarine (IC50 = 43 -
82 nM)
α2β2: DHβE (KB = 0.9 μM), tubocurarine
(KB = 1.4 μM); α2β4: DHβE (KB = 3.6
μM), tubocurarine (KB = 4.2 μM)
α3β2: DHβE (KB = 1.6 μM, IC50 = 2.0
μM), tubocurarine (KB = 2.4 μM); α3β4:
DHβE (KB = 19 μM, IC50 = 26 μM),
tubocurarine (KB = 2.2 μM)
α4β2: DHβE (KB = 0.1 μM; IC50 =
0.08 - 0.9 μM), tubocurarine (KB = 3.2
μM, IC50 = 34 μM); α4β4: DHβE (KB
= 0.01 μM, IC50 = 0.19 – 1.2 μM),
tubocurarine (KB = 0.2 μM, IC50 = 50
μM)
Selective agonists succinylcholine (selective for (α1)2β1γδ) – – varenicline [70], rivanicline [91],
TC-2559 (α4β2) [65]
Selective antagonists α-bungarotoxin, α-conotoxin GI,
α-conotoxin MI, pancuronium, waglerin-1
(selective for (α1)2β1δ)
– α-conotoxin AuIB (α3β4), α-conotoxin MII
(α3β2), α-conotoxin PnIA (α3β2),
α-conotoxin TxIA (α3β2), α-conotoxin-GIC
(α3β2)
–
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Nomenclature nicotinic acetylcholine receptor α1
subunit
nicotinic acetylcholine receptor α2
subunit
nicotinic acetylcholine receptor α3
subunit
nicotinic acetylcholine receptor α4
subunit
Channel blockers gallamine ((α1)2β1γδ and (α1)2β1δ)
(pIC50 ∼6), mecamylamine ((α1)2β1δ)
(pIC50 ∼5.8)
hexamethonium, mecamylamine mecamylamine (α3β4) (pIC50 6.4),
mecamylamine (α3β2) (pIC50 5.1),
A-867744 (α3β4) [240], NS1738 (α3β4)
[361], hexamethonium (α3β4),
hexamethonium (α3β2)
mecamylamine (α4β4) (pIC50
5.3–6.5), mecamylamine (α4β2)
(pIC50 5.4–5.4), hexamethonium
(α4β2) (pIC50 4.5–5.2),
hexamethonium (α4β4) (pIC50 4),
A-867744 (α4β2) [240], NS1738
(α4β2) [361]
Allosteric modulators – LY2087101 (Positive) [42] – LY2087101 (Positive) [42]
Selective allosteric
modulators
– – – NS9283 (Positive) [216]
Labelled ligands [125I]α-bungarotoxin (Selective
Antagonist), [3H]α-bungarotoxin (Selective
Antagonist)
[125I]epibatidine (Agonist),
[3H]epibatidine (Agonist),
[3H]cytisine (Agonist)
[125I]epibatidine (Agonist), [3H]epibatidine
(Agonist), [3H]cytisine (Agonist)
[125I]epibatidine (Agonist),
[3H]epibatidine (Agonist), [3H]cytisine
(Agonist), [125I]epibatidine (Agonist),
[3H]epibatidine (Agonist), [3H]nicotine
(Agonist) – Rat, [3H]cytisine (Agonist)
Functional Characteristics (α1)2βγδ: PCa/PNa = 0.16 - 0.2, Pf = 2.1 –
2.9%; (α1)2βδ: PCa/PNa = 0.65 – 1.38, Pf
= 4.1 – 7.2%
α2β2: PCa/PNa ˜1.5 α3β2: PCa/PNa = 1.5; α3β4: PCa/PNa =
0.78 - 1.1, Pf = 2.7 – 4.6%
α4β2: PCa/PNa = 1.65, Pf = 2.6 –
2.9%; α4β4: Pf = 1.5 – 3.0 %
Nomenclature nicotinic acetylcholine receptor α5 subunit nicotinic acetylcholine receptor α6 subunit nicotinic acetylcholine receptor α7 subunit
HGNC, UniProt CHRNA5, P30532 CHRNA6, Q15825 CHRNA7, P36544
Commonly used
antagonists
– α6/α3β2β3 chimera: DHβE (IC50 = 1.1 μM) (α7)5: DHβE (IC50 = 8 - 20 μM); (α7)5: tubocurarine
(IC50 = 3.1 μM)
Selective agonists – – encenicline (Partial agonist) [247, 280], AQW051
([125I]α- bungarotoxin binding assay) [167], 4BP-TQS
(allosteric) [124], A-582941 ((α7)5) [33], PHA-543613
((α7)5) [385], PHA-709829 ((α7)5) [2], PNU-282987
((α7)5) [36], bradanicline ((α7)5) [139]
Selective antagonists α-conotoxin MII, α-conotoxin PnIA, α-conotoxin TxIA,
α-conotoxin-GIC
α-conotoxin MII (α6β2*), α-conotoxin MII [H9A, L15A]
(α6β2β3), α-conotoxin PIA (α6/α3β2β3 chimera)
α-bungarotoxin ((α7)5), α-conotoxin ArIB ((α7)5),
α-conotoxin ImI ((α7)5), methyllycaconitine ((α7)5)
Channel blockers – mecamylamine (α6/α3β2β3 chimera) (pIC50 5),
hexamethonium (α6/α3β2β3 chimera) (pIC50 4)
mecamylamine ((α7)5) (pIC50 4.8)
Allosteric modulators – – A-867744 (Positive) [240], LY2087101 (Positive) [42],
NS1738 (Positive) [361]
Searchable database: http://www.guidetopharmacology.org/index.jsp Nicotinic acetylcholine receptors S152
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. British Journal of Pharmacology (2017) 174, S130–S159
(continued)
Nomenclature nicotinic acetylcholine receptor α5 subunit nicotinic acetylcholine receptor α6 subunit nicotinic acetylcholine receptor α7 subunit
Selective allosteric
modulators
– – JNJ1930942 (Positive) [87], PNU-120596 (Positive) [161]
Labelled ligands – [3H]epibatidine (Agonist) – Chicken,
[125I]α-conotoxin MII (Antagonist)
[3H]epibatidine (Agonist), [3H]A-585539 (Agonist) [7],
[3H]AZ11637326 (Agonist) [126], [125I]α-bungarotoxin
(Selective Antagonist) (pKd 8.3–9.1),
[3H]α-bungarotoxin (Selective Antagonist) (pKd
8.3–9.1), [3H]methyllycaconitine (Antagonist) (pKd 8.7)
– Rat
Functional Characteristics – – PCa/PNa = 6.6-20, Pf = 8.8 - 11.4%
Nomenclature nicotinic acetylcholine receptor α8 subunit (avian) nicotinic acetylcholine receptor α9 subunit nicotinic acetylcholine receptor α10 subunit
HGNC, UniProt – CHRNA9, Q9UGM1 CHRNA10, Q9GZZ6
Commonly used
antagonists
(α8)5: α-bungarotoxin > atropine ≥ tubocurarine ≥
strychnine
(α9)5: α-bungarotoxin > methyllycaconitine >
strychnine ˜ tropisetron > tubocurarine; α9α10:
α-bungarotoxin > tropisetron = strychnine >
tubocurarine
α9α10: α-bungarotoxin > tropisetron = strychnine >
tubocurarine
Selective antagonists – α-bungarotoxin ((α9)5), α-bungarotoxin (α9α10),
α-conotoxin RgIA (α9α10), muscarine ((α9)5),
muscarine (α9α10), nicotine ((α9)5), nicotine (α9α10),
strychnine ((α9)5), strychnine (α9α10)
α-bungarotoxin (α9α10), α-conotoxin RgIA (α9α10),
muscarine (α9α10), nicotine (α9α10), strychnine
(α9α10)
Labelled ligands [3H]epibatidine ((α8)5) (pKd 9.7), [
125I]α-bungarotoxin
(native α8*) (pKd 8.3), [
3H]α-bungarotoxin (native α8*)
(pKd 8.3)
[3H]methyllycaconitine (Antagonist) (pKd 8.1),
[125I]α-bungarotoxin (Antagonist), [3H]α-bungarotoxin
(Antagonist)
[3H]methyllycaconitine (Antagonist) (pKd 8.1)
Functional Characteristics – (α9)5: PCa/PNa = 9; α9α10: PCa/PNa = 9, Pf = 22% α9α10: PCa/PNa = 9, Pf = 22%
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Nomenclature nicotinic acetylcholine
receptor β1 subunit
nicotinic acetylcholine
receptor β2 subunit
nicotinic acetylcholine
receptor β3 subunit
nicotinic acetylcholine
receptor β4 subunit
nicotinic acetylcholine
receptor γ subunit
nicotinic acetylcholine
receptor δ subunit
nicotinic acetylcholine
receptor  subunit
HGNC, UniProt CHRNB1, P11230 CHRNB2, P17787 CHRNB3, Q05901 CHRNB4, P30926 CHRNG, P07510 CHRND, Q07001 CHRNE, Q04844
Antagonists – – – – – PhTX-11 (pIC50
6.2–6.3) [346]
–
Comments Ligand interaction data for hetero-oligomeric receptors containing the β1 receptors are listed under the α1 receptors.
Comments: Commonly used agonists of nACh receptors that
display limited discrimination in functional assays between re-
ceptor subtypes include A-85380, cytisine, DMPP, epibatidine,
nicotine and the natural transmitter, acetylcholine (ACh). A sum-
mary of their proﬁle across differing receptors is provided in [128]
and quantitative data across numerous assay systems are summa-
rized in [177]. Quantitative data presented in the table for com-
monly used antagonists and channel blockers for human receptors
studied under voltage-clamp are from [46, 58, 291, 292, 295, 386].
Type I PAMs increase peak agonist-evoked responses but have lit-
tle, or no, effect on the rate of desensitization of α7 nicotinic ACh
receptors whereas type II PAMs also cause a large reduction in de-
sensitization (reviewed in [384]).
Further reading on Nicotinic acetylcholine receptors
Auerbach, A. (2015) Agonist activation of a nicotinic acetylcholine receptor. Neuropharmacology 96:
150-6 [PMID:25446670]
Bertrand, D et al. (2015) Therapeutic Potential of alpha7 Nicotinic Acetylcholine Receptors. Phar-
macol Rev 67: 1025-1073 [PMID:26419447]
Bouzat, C et al. (2017) Nicotinic acetylcholine receptors at the single-channel level. Br J Pharmacol
[PMID:28261794]
Chatzidaki, A et al. (2015) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Phar-
macol 97: 408-17 [PMID:26231943]
Corradi, J et al. (2016) Understanding the Bases of Function and Modulation of alpha7 Nicotinic
Receptors: Implications for Drug Discovery. Mol Pharmacol 90: 288-99 [PMID:27190210]
Crespi, A et al. (2017) Proteins and chemical chaperones involved in neuronal nicotinic receptor
expression and function: an update. Br J Pharmacol [PMID:28294298]
Dineley, KT et al. (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends
Pharmacol Sci 36: 96-108 [PMID:25639674]
Lukas, RJ et al. (1999) International Union of Pharmacology. XX. Current status of the nomen-
clature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401
[PMID:10353988]
Stokes, C et al. (2015) Looking below the surface of nicotinic acetylcholine receptors. Trends Phar-
macol Sci 36: 514-23 [PMID:26067101]
Wang, J et al. (2017) Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic
acetylcholine receptors. Br J Pharmacol [PMID:28199738]
Wu, J et al. (2016) Heteromeric alpha7beta2 Nicotinic Acetylcholine Receptors in the Brain. Trends
Pharmacol Sci 37: 562-74 [PMID:27179601]
P2X receptors
Ligand-gated ion channels → P2X receptors
Overview: P2X receptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on P2X Receptors [71, 196])
have a trimeric topology [179, 191, 275] with two putative TM do-
mains, gating primarily Na+, K+ and Ca2+, exceptionally Cl-. The
Nomenclature Subcommittee has recommended that for P2X re-
ceptors, structural criteria should be the initial criteria for nomen-
clature where possible. X-ray crystallography indicates that func-
tional P2X receptors are trimeric and three agonist molecules are
required to bind to a single receptor in order to activate it [125,
138, 191, 242]. Native receptors may occur as either homotrimers
(e.g. P2X1 in smooth muscle) or heterotrimers (e.g. P2X2:P2X3
in the nodose ganglion and P2X1:P2X5 in mouse cortical astro-
cytes, [213]. P2X2, P2X4 and P2X7 receptors have been shown to
form functional homopolymers which, in turn, activate pores per-
meable to low molecular weight solutes [349]. The hemi-channel
pannexin-1 has been implicated in the pore formation induced by
P2X7 [298], but not P2X2 [57], receptor activation.
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Nomenclature P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7
HGNC, UniProt P2RX1, P51575 P2RX2, Q9UBL9 P2RX3, P56373 P2RX4, Q99571 P2RX5, Q93086 P2RX6, O15547 P2RX7, Q99572
Endogenous agonists – ATP [167] – Rat ATP [168] ATP [168] ATP [168] – Rat ATP [168] – Rat ATP [168]
Agonists αβ-meATP, BzATP,
L-βγ-meATP
– αβ-meATP, BzATP – – – –
Antagonists TNP-ATP (pIC50 ∼8.9)
[370], Ip5I (pIC50
∼8.5), NF023 (pIC50
∼6.7), NF449 (pIC50
∼6.3) [195]
NF770 (pIC50 7–8)
[281], NF778 (pIC50
7–8) [281], PSB-10211
(pIC50 ∼7) [281]
TNP-ATP (pIC50 ∼8.9)
[370], AF-906 (pIC50
8.9) [170], AF-219
(pIC50 8.5) [170],
A317491 (pIC50 ∼7.5)
[173]
5-BDBD (pIC50 5–6) [170,
281], BX-430 (pIC50 5–6)
[170, 281], PSB-12062
(pIC50 5–6) [170, 281],
paroxetine (pIC50 5–6)
[175, 281]
– – AZ10606120 (pKd 8.9) [250],
A804598 (pIC50 ∼8),
brilliant blue G (pIC50 ∼8)
[180], A839977 (pIC50 ∼7.7)
[93, 95, 149], A740003
(pIC50 7.4) [150],
decavanadate (pA2 = 7.4)
(pA2 7.4) [255], A438079
(pIC50 ∼6.9) [93],
AZ11657312 (salt free) (pA2
6.1) [11]
Selective antagonists – – – – – – JNJ-479655 (pKi 7.9) [31]
Allosteric modulators – – – – – – AZ10606120 (Negative)
[250], GW791343 (Positive)
[250, 252] – Rat, GW791343
(Negative) [250, 252]
Selective allosteric
modulators
MRS 2219 (Positive)
[169]
– – ivermectin (Positive)
(pEC50 ∼6.6) [197] – Rat
– – chelerythrine (Negative)
(pIC50 5.2) [329],
AZ11645373 (Negative) [253,
345], KN62 (Negative) [122,
329], ivermectin (Positive)
[283]
Comments – – – – – – Effects of the allosteric
modulators at P2X7 receptors
are species-dependent.
Comments: A317491 and RO3 also block the P2X2:P2X3 het-
eromultimer [113, 173]. NF449, A317491 and RO3 are more than
10-fold selective for P2X1 and P2X3 receptors, respectively.
Agonists listed show selectivity within recombinant P2X receptors
of ca. one order of magnitude. A804598, A839977, A740003 and
A438079 are at least 10-fold selective for P2X7 receptors and show
similar afﬁnity across human and rodent receptors [93, 95, 149].
Several P2X receptors (particularly P2X1 and P2X3) may be in-
hibited by desensitisation using stable agonists (e.g. αβ-meATP);
suramin and PPADS are non-selective antagonists at rat and hu-
man P2X1–3,5 and hP2X4, but not rP2X4,6,7 [45], and can also
inhibit ATPase activity [72]. Ip5I is inactive at rP2X2, an an-
tagonist at rP2X3 (pIC50 5.6) and enhances agonist responses
at rP2X4 [199]. Antagonist potency of NF023 at recombinant
P2X2, P2X3 and P2X5 is two orders of magnitude lower than
that at P2X1 receptors [342]. The P2X7 receptor may be in-
hibited in a non-competitive manner by the protein kinase
inhibitors KN62 and chelerythrine [329], while the p38 MAP ki-
nase inhibitor GTPγS and the cyclic imide AZ11645373 show a
species-dependent non-competitive action [94, 253, 254, 345].
The pH-sensitive dye used in culture media, phenol red, is also
reported to inhibit P2X1 and P2X3 containing channels [200].
Some recombinant P2X receptors expressed to high density bind
[35S]ATPγS and [3H]αβ-meATP, although the latter can also bind
to 5′-nucleotidase [251]. [3H]A317491 and [3H]A804598 have
been used as high afﬁnity antagonist radioligands for P2X3 (and
P2X2/3) and P2X7 receptors, respectively [95].
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Further reading on P2X receptors
Coddou C et al. (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol
Rev 63: 641-83 [PMID:21737531]
Habermacher C et al. (2016) Molecular structure and function of P2X receptors. Neuropharmacology
104: 18-30 [PMID:26231831]
Jacobson, KA et al. (2016) Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharma-
cology 104: 31-49 [PMID:26686393]
Khakh BS et al. (2001) International Union of Pharmacology. XXIV. Current status of the
nomenclature and properties of P2X receptors and their subunits Pharmacol Rev 53: 107-118
[PMID:11171941]
North, RA. (2016) P2X receptors. Philos Trans R Soc Lond B Biol Sci 371: [PMID:27377721]
ZAC
Ligand-gated ion channels → ZAC
Overview: The zinc-activated channel (ZAC, nomenclature as
agreed by the NC-IUPHAR Subcommittee for the Zinc Ac-
tivated Channel) is a member of the Cys-loop family that in-
cludes the nicotinic ACh, 5-HT3, GABAA and strychnine-sensitive
glycine receptors [78, 155, 363]. The channel is likely to exist as
a homopentamer of 4TM subunits that form an intrinsic cation
selective channel equipermeable to Na+, K+ and Cs+, but imper-
meable to Ca2+ andMg2+ [363]. ZAC displays constitutive activity
that can be blocked by tubocurarine and high concentrations of
Ca2+ [363]. Although denoted ZAC, the channel is more potently
activated by protons and copper, with greater and lesser efﬁcacy
than zinc, respectively [363]. ZAC is present in the human, chim-
panzee, dog, cow and opossum genomes, but is functionally ab-
sent from mouse, or rat, genomes [78, 155].
Nomenclature ZAC
HGNC, UniProt ZACN, Q401N2
Endogenous agonists H+ [363], Cu2+ [363], Zn2+ [78, 363]
Antagonists tubocurarine (pIC50 5.2) [78], Ca2+ (pIC50 2) [363]
Functional Characteristics Outwardly rectifying current (both constitutive and evoked by Zn2+)
Comments: The ZAC subunit does not appear to exist in the mouse or rat genomes [78]. Although tabulated as an antagonist, it is possible that tubocurarine acts as a channel blocker. Antagonism
by Ca2+ is voltage-independent. ZAC is not activated (at 1 mM) by transition metals including Fe2+, Co2+, Ni2+, Cd2+, or Al3+ [363]. The concentration response relationship to Cu2+ is biphasic, with
concentrations exceeding 30 μM being associated with reduced activation [363].
Further reading on ZAC
Collingridge, GL et al. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology
56: 2-5 [PMID:18655795]
Peralta, FA et al. (2016) Zinc as Allosteric Ion Channel Modulator: Ionotropic Receptors as Metallo-
proteins. Int J Mol Sci 17: [PMID:27384555]
Trattnig, SM et al. (2016) Copper and protons directly activate the zinc-activated channel. Biochem
Pharmacol 103: 109-17 [PMID:26872532]
Searchable database: http://www.guidetopharmacology.org/index.jsp ZAC S156
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. British Journal of Pharmacology (2017) 174, S130–S159
References
1. Abi-Dargham A et al. (1993) [8419547]
2. Acker BA et al. (2008) [18490160]
3. Ahrens J et al. (2009) [19204413]
4. Akopian AN et al. (2000) [10923674]
5. Albaugh PA et al. (2002) [12408715]
6. Albuquerque EX et al. (2009) [19126755]
7. Anderson DJ et al. (2008) [17959745]
8. Andrey F et al. (2005) [16085050]
9. Araud T et al. (2010) [20346921]
10. AstraZeneca. AZ11657312. Accessed on 12/
09/2014. astrazeneca.com.
11. Atack JR. (2010) [21309116]
12. Atack JR. (2008) [18482097]
13. Atlason PT et al. (2010) [20837679]
14. Auberson YP et al. (2002) [11909726]
15. Babinski K et al. (2000) [10842183]
16. Babinski K et al. (1999) [9886053]
17. Baconguis I et al. (2014) [24507937]
18. Bang-Andersen B et al. (2011) [21486038]
19. Barker PM et al. (1990) [2391659]
20. Barnard EA et al. (1998) [9647870]
21. Barnes NM et al. (2009) [18761359]
22. Baron A et al. (2015) [25613302]
23. Baron A et al. (2001) [11457851]
24. Baron A et al. (2008) [18256271]
25. Barrera NP et al. (2005) [16116092]
26. Belelli D et al. (1995) [8848005]
27. Belelli D et al. (2009) [19828786]
28. Belelli D et al. (2005) [15959466]
29. Bettini E et al. (2010) [20810618]
30. Betz H et al. (2006) [16805771]
31. Bhattacharya A et al. (2013) [23889535]
32. Bianchi MT et al. (2003) [14645489]
33. Bitner RS et al. (2007) [17898229]
34. Blanchard MG et al. (2012) [21943094]
35. Boase NA et al. (2011) [21505443]
36. Bodnar AL et al. (2005) [15715459]
37. Bohlen CJ et al. (2011) [22094702]
38. Bonin RP et al. (2008) [18201756]
39. Bonny O et al. (2000) [10760060]
40. Bowie D. (2010) [19822544]
41. Brady CA et al. (2001) [11489465]
42. Broad LM et al. (2006) [16738207]
43. Brown N et al. (2002) [12145096]
44. Brüss M et al. (2000) [11111833]
45. Buell G et al. (1996) [8598206]
46. Buisson B et al. (1996) [8987816]
47. Cadiou H et al. (2007) [18045919]
48. Canessa CM et al. (1993) [8381523]
49. Canessa CM et al. (1994) [8107805]
50. Cantrell BE et al. (1996) [8809152]
51. Capogna M et al. (2011) [21145601]
52. Cavara NA et al. (2008) [18654865]
53. Celie PH et al. (2004) [15046723]
54. Changeux JP. (2010) [20055696]
55. Changeux JP et al. (2008) [18262468]
56. Chatterton JE et al. (2002) [11823786]
57. Chaumont S et al. (2008) [18689682]
58. Chavez-Noriega LE et al. (1997) [8996215]
59. Chazot PL et al. (1998) [9721050]
60. Chebib M. (2004) [15566397]
61. Chen CC et al. (1998) [9707631]
62. Chen PE et al. (2008) [17962328]
63. Chen PE et al. (2006) [16474411]
64. Chen X et al. (2005) [15955877]
65. Chen Y et al. (2003) [12871651]
66. Chen ZW et al. (2007) [17083446]
67. Chopra B et al. (2000) [10780999]
68. Chu XP et al. (2006) [16707785]
69. Chu XP et al. (2004) [15470133]
70. Coe JW et al. (2005) [16171993]
71. Collingridge GL et al. (2009) [18655795]
72. Crack BE et al. (1994) [7889301]
73. Cull-Candy S et al. (2006) [16713244]
74. Cull-Candy SG et al. (2004) [15494561]
75. Daniel C et al. (2009) [19909284]
76. Das P et al. (2003) [14625088]
77. Davies PA et al. (1999) [9950429]
78. Davies PA et al. (2003) [12381728]
79. de Weille JR et al. (1998) [9744806]
80. Debonneville C et al. (2001) [11742982]
81. Deeb TZ et al. (2009) [19131665]
82. Dellisanti CD et al. (2007) [17643119]
83. Demir R et al. (2009) [19307742]
84. Deval E et al. (2011) [21508231]
85. Deval E et al. (2008) [18923424]
86. Dingledine R et al. (1999) [10049997]
87. Dinklo T et al. (2011) [21084390]
88. Diochot S et al. (2004) [15044953]
89. Diochot S et al. (2012) [23034652]
90. Diochot S et al. (2007) [17113616]
91. Dogruer D et al. (2004) [14698195]
92. Donier E et al. (2008) [18662336]
93. Donnelly-Roberts DL et al. (2007)
[17471177]
94. Donnelly-Roberts DL et al. (2004)
[14634045]
95. Donnelly-Roberts DL et al. (2009)
[19558545]
96. Dravid SM et al. (2007) [17303642]
97. Du J et al. (2014) [24889629]
98. Dubin AE et al. (1999) [10521471]
99. Dubé GR et al. (2005) [16061325]
100. Dunlop J et al. (2008) [18356919]
101. Edman S et al. (2012) [22579927]
102. Edwards E et al. (1996) [8891244]
103. Eichler SA et al. (2008) [19210758]
104. Enuka Y et al. (2012) [22207244]
105. Erreger K et al. (2004) [15701057]
106. Erreger K et al. (2007) [17622578]
107. Escoubas P et al. (2000) [10829030]
108. Esteban JA. (2008) [18026130]
109. Farrant M et al. (2005) [15738957]
110. Feng B et al. (2004) [14718249]
111. Fisher JL. (2002) [12021393]
112. Fisher JL. (2009) [18585399]
113. Ford AP et al. (2006) [16465177]
114. Friedrich B et al. (2003) [12632189]
115. Friese MA et al. (2007) [17994101]
116. Frizelle PA et al. (2006) [16778008]
117. Frlund B et al. (2002) [12171573]
118. Fucile S et al. (2000) [11144365]
119. Furukawa H et al. (2005) [16281028]
120. Garcia-Caballero A et al. (2009) [19541605]
121. García-Añoveros J et al. (1997) [9037075]
122. Gargett CE et al. (1997) [9113369]
123. Gielen M et al. (2009) [19404260]
124. Gill JK et al. (2011) [21436053]
125. Gonzales EB et al. (2009) [19641589]
126. Gordon JC et al. (2010) [20674564]
127. Gotti C et al. (2009) [19481063]
128. Gotti C et al. (2006) [16876883]
129. Grudzinska J et al. (2005) [15748848]
130. Gründer S et al. (2000) [10852210]
131. Gründer S et al. (2015) [25585135]
132. Guan Y et al. (2005) [16007095]
133. Hadingham KL et al. (1996) [8632757]
134. Hadingham KL et al. (1995) [8719414]
135. Hanna MC et al. (2000) [10854267]
136. Hansen KB et al. (2012) [22553026]
137. Hanukoglu I et al. (2016) [26772908]
138. Hattori M et al. (2012) [22535247]
139. Hauser TA et al. (2009) [19482012]
140. Hejazi N et al. (2006) [16332990]
141. Hemmings HC et al. (2005) [16126282]
142. Henson MA et al. (2010) [20097255]
143. Herd MB et al. (2007) [17531325]
144. Hibbs RE et al. (2011) [21572436]
145. Hilf RJ et al. (2009) [19646860]
146. Hirata T et al. (2007) [17652911]
147. Hirzel K et al. (2006) [17114051]
148. Holbrook JD et al. (2009) [19012743]
149. Honore P et al. (2009) [19464323]
150. Honore P et al. (2006) [16982702]
151. Hope AG et al. (1993) [7683998]
152. Hope AG et al. (1996) [8818349]
153. Horak M et al. (2006) [16257494]
154. Hosie AM et al. (2007) [17560657]
155. Houtani T et al. (2005) [16083862]
156. Howard RJ et al. (2011) [21730162]
157. Hoyer D et al. (1994) [7938165]
158. Hu XQ et al. (2008) [18187416]
159. Huang Q et al. (1998) [9767648]
160. Hummler E et al. (1996) [8589728]
161. Hurst RS et al. (2005) [15858066]
162. Hurth K et al. MEDI 222: Identiﬁcation of
AQW051, an alpha7 nicotinic acetylcholine
receptor partial agonist for the treatment
of cognitive impairment associated with
schizophrenia. Accessed on 06/04/2014.
ACS Med Chem Meeting Abstracts, March
2014.
163. Isaac JT et al. (2007) [17582328]
164. Isenberg KE et al. (1993) [7509203]
165. Jackson AC et al. (2011) [21521608]
166. Jacob TC et al. (2008) [18382465]
167. Jacobson KA et al. (2009) [18600475]
168. Jacobson KA et al. (2002) [12213051]
169. Jacobson KA et al. (1998) [9632352]
170. Jacobson KA et al. (2016) [26686393]
171. Jane DE et al. (2009) [18793656]
172. Jane DE et al. (2000) Glutamate receptor
ion channels: activators and inhibitors. In
Handbook of Experimental Pharmacology, Phar-
macology of Ionic Channel Function: Activators
and Inhibitors Edited by Endo M, Kurachi Y,
Mishina M: Springer: 415-478
173. Jarvis MF et al. (2002) [12482951]
174. Jarvis MF et al. (2009) [18657557]
175. Jasti J et al. (2007) [17882215]
176. Jensen AA et al. (2008) [18597859]
Searchable database: http://www.guidetopharmacology.org/index.jsp References S157
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. British Journal of Pharmacology (2017) 174, S130–S159
177. Jensen AA et al. (2005) [16033252]
178. Jensen TN et al. (2006) [16647053]
179. Jiang LH et al. (2003) [14523092]
180. Jiang LH et al. (2000) [10860929]
181. Johnston GA. (2005) [15974965]
182. Johnston GA et al. (2010) [20963487]
183. Jones AK et al. (2010) [20674046]
184. Kaczor AA et al. (2010) [20491632]
185. Kalamida D et al. (2007) [17651090]
186. Kapeller J et al. (2011) [21192076]
187. Karakas E et al. (2011) [21677647]
188. Karim N et al. (2013) [23385381]
189. Karnovsky AM et al. (2003) [14597179]
190. Kassack MU et al. (2004) [15072843]
191. Kawate T et al. (2009) [19641588]
192. Kellenberger S et al. (2003) [14500741]
193. Kellenberger S et al. (2015) [25287517]
194. Kelley SP et al. (2003) [12867984]
195. Kew JN et al. (2005) [15731895]
196. Khakh BS et al. (2001) [11171941]
197. Khakh BS et al. (1999) [10460235]
198. Khom S et al. (2010) [20718740]
199. King BF et al. (1999) [10556935]
200. King BF et al. (2005) [15778739]
201. Kirsch J. (2006) [16807723]
202. Kitamura K et al. (2010) [20535627]
203. Kleyman TR et al. (2009) [19401469]
204. Kneussel M et al. (2007) [17504238]
205. Korpi ER et al. (2007) [17591542]
206. Korpi ER et al. (2002) [12126658]
207. Kreple CJ et al. (2014) [24952644]
208. Krishek BJ et al. (1998) [9508826]
209. Krogsgaard-Larsen P et al. (2002)
[12469353]
210. Kulagowski JJ et al. (1994) [8182696]
211. Kumar J et al. (2013) [22974439]
212. Kuner T et al. (1996) [8642401]
213. Lalo U et al. (2008) [18495881]
214. Lankiewicz S et al. (1998) [9463477]
215. Laube B et al. (2002) [12413807]
216. Lee CH et al. (2011) [21763685]
217. Leeson PD et al. (1992) [1534584]
218. Lerma J. (2006) [16361114]
219. Lerma J. (2011) [21709676]
220. Li GD et al. (2009) [19282280]
221. Li GD et al. (2006) [17093081]
222. Lin SH et al. (2015) [25828470]
223. Lingueglia E et al. (1997) [9368048]
224. Liu SJ et al. (2007) [17275103]
225. Lochner M et al. (2010) [20409468]
226. Lodge D. (2009) [18765242]
227. Lofﬁng J et al. (2009) [19277701]
228. Lozovaya N et al. (2005) [16107637]
229. Lu M et al. (2008) [18326490]
230. Lukas RJ et al. (1999) [10353988]
231. Lummis SC et al. (2011) [21775477]
232. Luscher B et al. (2011) [21555068]
233. Lynch JW. (2009) [18721822]
234. Lynch JW. (2004) [15383648]
235. Ma HP et al. (2007) [17605040]
236. Madry C et al. (2008) [18711142]
237. Maekawa A et al. (2009) [19145783]
238. Maksay G et al. (2009) [19383091]
239. Malayev A et al. (2002) [11861317]
240. Malysz J et al. (2009) [19389923]
241. Mamet J et al. (2002) [12486159]
242. Mansoor SE et al. (2016) [27626375]
243. Maricq AV et al. (1991) [1718042]
244. Marra S et al. (2016) [26772186]
245. Mascia MP et al. (2000) [10908659]
246. Mayer ML. (2006) [16554805]
247. Mazurov AA et al. (2011) [21919481]
248. McKay S et al. (2012) [22022974]
249. Meier JC et al. (2005) [15895087]
250. Michel AD et al. (2008) [18071294]
251. Michel AD et al. (1995) [8548175]
252. Michel AD et al. (2008) [18660826]
253. Michel AD et al. (2009) [19309360]
254. Michel AD et al. (2006) [17031382]
255. Michel AD et al. (2006) [16487507]
256. Millar NS. (2008) [18246096]
257. Millar NS et al. (2009) [18723036]
258. Miller PS et al. (2005) [15905212]
259. Miller PS et al. (2010) [20096941]
260. Milstein AD et al. (2008) [18514334]
261. Miu P et al. (2001) [11406188]
262. Miyake A et al. (1995) [7565620]
263. Mochizuki S et al. (1999) [10204690]
264. Mochizuki S et al. (2000) [10884508]
265. Mody I et al. (2004) [15331240]
266. Morley RM et al. (2005) [15801853]
267. Morris RG et al. (2002) [12084777]
268. Moss SJ et al. (2001) [11283747]
269. Moura Barbosa AJ et al. (2010) [20724042]
270. Möhler H. (2007) [17394533]
271. Nakagawa T. (2010) [21080238]
272. Naur P et al. (2007) [17715062]
273. Neyton J et al. (2006) [16452656]
274. Ng CK et al. (2011) [21428815]
275. Nicke A et al. (1998) [9606184]
276. Niesler B. (2011) [21345729]
277. Niesler B et al. (2003) [12801637]
278. Niesler B et al. (2008) [18466097]
279. Niesler B et al. (2007) [17392525]
280. No authors listed. (2004) [15293871]
281. North RA et al. (2013) [23253448]
282. Nury H et al. (2011) [21248852]
283. Nörenberg W et al. (2012) [22506590]
284. Oertel J et al. (2007) [17145751]
285. Olsen RW et al. (2011) [21194017]
286. Olsen RW et al. (2009) [18760291]
287. Olsen RW et al. (2008) [18790874]
288. Paoletti P. (2011) [21395862]
289. Paoletti P et al. (2013) [23686171]
290. Paoletti P et al. (2007) [17088105]
291. Papke RL et al. (2008) [18448138]
292. Papke RL et al. (2001) [11303054]
293. Parker RM et al. (1996) [8994113]
294. Parker RM et al. (1996) [8936343]
295. Paul M et al. (2002) [11867382]
296. Pedregal C et al. (2000) [10821708]
297. Peigneur S et al. (2012) [22972919]
298. Pelegrin P et al. (2009) [19212823]
299. Perrais D et al. (2009) [18761361]
300. Perrais D et al. (2010) [20850188]
301. Peters JA et al. (2005) [16194573]
302. Pidoplichko VI et al. (2006) [16847263]
303. Pinheiro P et al. (2006) [16847640]
304. Pitt SJ et al. (2008) [18987182]
305. Planès C et al. (2007) [17338914]
306. Plested AJ. (2011) [21713670]
307. Pochynyuk O et al. (2008) [18981175]
308. Price MP et al. (1996) [8626462]
309. Pritchett DB et al. (1989) [2551039]
310. Ramerstorfer J et al. (2011) [21248110]
311. Richard K et al. (2004) [15498559]
312. Rodríguez-Moreno A et al. (2007)
[17981346]
313. Rossier BC et al. (2009) [18928407]
314. Rotin D et al. (2008) [18691017]
315. Rucktooa P et al. (2009) [19576182]
316. Rundström N et al. (1994) [8090751]
317. Rüsch D et al. (2007) [17360702]
318. Sagot E et al. (2008) [18578478]
319. Sakai H et al. (1999) J Physiol 2: 323-333
320. Sakai R et al. (2001) [11160654]
321. Saxena NC et al. (1997) [9203639]
322. Sayegh R et al. (1999) [10212217]
323. Schaefer L et al. (2000) [10767424]
324. Schild L. (2010) [20600867]
325. Scholze P et al. (1996) [8813598]
326. Seeburg PH et al. (2003) [12850211]
327. Semyanov A et al. (2004) [15111008]
328. Sergeeva OA et al. (2010) [20511229]
329. Shemon AN et al. (2004) [15210579]
330. Sherwood TW et al. (2011) [21715637]
331. Sieghart W. (2006) [17175817]
332. Sigel E et al. (2011) [21189125]
333. Sigel E et al. (2012) [23038269]
334. Sine SM et al. (2006) [16554804]
335. Skolnick P et al. (1997) [9353361]
336. Small B et al. (1998) [9849663]
337. Smith ES et al. (2007) [17258862]
338. Smith SS. (2013) [24027497]
339. Smothers CT et al. (2007) [17502428]
340. Sobolevsky AI et al. (2009) [19946266]
341. Solt K et al. (2005) [16081679]
342. Soto F et al. (1999) [10193905]
343. Staub O et al. (1996) [8665844]
344. Stewart A et al. (2003) [12623220]
345. Stokes L et al. (2006) [17031385]
346. Strmgaard K et al. (2002) [11934578]
347. Stórustovu SI et al. (2006) [16272218]
348. Sun H et al. (1999) [10381768]
349. Surprenant A et al. (2009) [18851707]
350. Taly A et al. (2009) [19721446]
351. Thompson AJ et al. (2011) [21505038]
352. Thompson AJ et al. (2011) [21059362]
353. Thompson AJ et al. (2010) [20849671]
354. Thompson AJ et al. (2008) [18311193]
355. Thompson AJ et al. (2006) [17073663]
356. Thompson AJ et al. (2007) [17373882]
357. Thompson AJ et al. (2011) [21708905]
358. Thompson SA et al. (2002) [12367611]
359. Thompson SA et al. (1999) [10455284]
360. Thompson SA et al. (2004) [15100159]
361. Timmermann DB et al. (2007) [17625074]
362. Tomita S. (2010) [20134027]
363. Trattnig SM et al. (2016) [26872532]
364. Traynelis SF et al. (1998) [9698310]
365. Traynelis SF et al. (2010) [20716669]
366. Tzvetkov MV et al. (2007) [17010535]
367. Ugawa S et al. (2001) [11588592]
368. Veleiro AS et al. (2009) [19199916]
369. Vick JS et al. (2015) [25592215]
370. Virginio C et al. (1998) [9614197]
371. Vithlani M et al. (2011) [21742794]
372. Voilley N et al. (2001) [11588175]
373. Vukicevic M et al. (2006) [16282326]
374. Wafford KA et al. (2009) [18762200]
Searchable database: http://www.guidetopharmacology.org/index.jsp References S158
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. British Journal of Pharmacology (2017) 174, S130–S159
375. Waldmann R et al. (1997) [9261094]
376. Waldmann R et al. (1997) [9062189]
377. Waldmann R et al. (1996) [8631835]
378. Wallner M et al. (2006) [16814864]
379. Walstab J et al. (2010) [20522555]
380. Walstab J et al. (2010) [20621123]
381. Webb TI et al. (2007) [17692006]
382. Wemmie JA et al. (2013) [23783197]
383. Wiemuth D et al. (2014) [24365967]
384. Williams DK et al. (2011) [21575610]
385. Wishka DG et al. (2006) [16821801]
386. Wu J et al. (2006) [16825297]
387. Wu J et al. (2011) [21787755]
388. Wyllie DJ et al. (2013) [23376022]
389. Xiong W et al. (2011) [21460829]
390. Xiong ZG et al. (2007) [17127388]
391. Yang KC et al. (2009) [19498417]
392. Yang L et al. (2014) [25114023]
393. Yang LM et al. (2006) [16476738]
394. Yang Z et al. (2008) [18755158]
395. Yang Z et al. (2007) [17714449]
396. Yevenes GE et al. (2010) [20647311]
397. Yevenes GE et al. (2006) [17040914]
398. Yevenes GE et al. (2003) [12858180]
399. Yevenes GE et al. (2011) [21557733]
400. You H et al. (2010) [20638393]
401. Young GT et al. (2008) [18791069]
402. Yu Y et al. (2010) [20920791]
403. Yuzaki M. (2003) [12725908]
404. Zezula J et al. (1996) [8773466]
405. Zha XM et al. (2009) [19218436]
406. Zhang D et al. (2001) [11239575]
407. Zhou LM et al. (1997) [8996224]
408. Ziemann AE et al. (2009) [19945383]
Searchable database: http://www.guidetopharmacology.org/index.jsp References S159
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full
